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INTRODUCTION 
  Siddha medicine is the oldest medical system developed by 18 Siddhars.The word siddha 
comes from the word “SIDDHI‖which means  to attain “PERFECTION OR HEAVENLY 
BLISS‖.     
 Indigenous medicines including siddha of India are getting much attention nowadays for 
treating various diseases. This due to their potency and less side effect (Mitchell, 2003). During 
the past two decade,traditional system of medicine have become a topic of global importance. In 
south India siddha still remains dominant compared to modern medicine particularly for the 
treatment of a variety of chronic disease conditions among masses. 
 In 20th century usage of herbal based medicinal therapy gained importance and found 
their place in 40% of prescription because of their lesser side effects. on par with other chemical 
drugs. A remarkable increase in the usage of medicinal plant products in the form of plant 
extracts and their active components etc.Have been observed in the past decade, among the 
world population as a primary health care aid. 
 Yugi muni had done a lot of contribution to the siddha system, includes the classification 
of disease into 4448. AAN MALADU is one among them. According to Yugi muni in aan 
maladu the semen exhibits the following characters such as absence of sweetness, buoyancy on 
water. He further explained the character of urine in aan maldu as froth in urine and symptoms 
like absence of virility. 
 Sukkilam one among the seven udal thathukkal is affected in Aan maladu. It can be 
correlated with male Infertility in modern science . Most cases of male infertility are due to an 
abnormal sperm count or low sperm motility. Infertility is the inability of a sexually active, non 
contraception couple to achieve pregnancy in one year.  There was a time when infertility was 
only limited to women. In present scenario male infertility is blamed in 50 % of cases where 
couples could not conceive naturally. Male infertility is a global problem in the field of 
reproductive health. . 
 Infertility bears a social stigma.The incidence of infertility among males 40% females 
 40% and both sex 20%. 
2 
 
 Most of the cases hail from IT back ground, chemical industry, oil refineraries, viral 
infections at an early age in male child, trauma(testes), endocrine disorder ,low economic status, 
can also lead to rise in infertility rate. The heat generated from laptops can make an impact 
sperm production and development making it difficult to conceive down the road. As per WHO 
guidelines a report with count less than 15 million / ml is oligospermia. The most common 
problems men face are low sperm count, morphology abnormalities and motility of sperm. 
 The research study entitled Aan maldu ( Male infertility) mainly focus on outcome of 
qualitative and quantitative analysis of semen in oligospermia patients with the Study drug 
Poonakali vithai chooranam . Poonaikali vithai chooranam is a polyherbal compound based on 
the activities of the drug. The Study drug poonaikali vithai chooranam being the poly herbal 
formulation consists of ingredients possessing anti oxidants ( kayakalpha drugs ) and aphrodisiac 
properties. 
 Since the Study medicine is yet to be documented for its efficacy, it is essential to do 
safety studies before going for clinical study.
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AIM AND OBJECTIVES 
Aim: 
 To document the effective Siddha Medicine Poonaikali vithai Chooranam (Internal 
medicines) in the management of AAN Maladu ( male infertility) 
Primary Objective: 
 To evaluate the therapeutic efficacy of Poonaikali vithai Chooranam( Internal medicines)  
based on Semen analysis in the treatment of AAN Maladu  ( male infertility) 
Secondary Objective: 
 To prepare the trail Medicine as per the text Gunapadam Mooligai Vagupu.  
Author: Vaithiya rathinam K.S Murugesa muthalaiyar: 1st Edison  pg no 708  
  (publication year 1936)  
 To collect raw drugs and to get Authentication. 
 To evaluate the safety profile of the trial drug in animal models as per  
OECD guidelines -423 
 To evaluate the phytochemical analysis of the drug. 
 To study the changes in special investigation –Semen Analysis Before and After 
treatment. 
 To evaluate the Infertility Percentage among the study patients with respect to 
age,occupation, and socioeconomic structure.
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The characteristic features of AAN MALADU 
 The semen in aanmaladu will be devoid of sweetness and life and will float on the surface 
of water. The urine also will be frothy. Such man will be incapable to impregnate women. 
DEVELOPMENT OF SPERM 
“  
 
 
!” -  
 In the above verses thirumolar states that the driving force the kundali arises in the sperm 
which in turn initates the anthakarnanam to bring changes in the ova during fertilization. 
5 ARTS OF SPERM 
1. Neekal 
2. Nelaipithal 
3. Nugarvithal 
4. Amaithiyakkal 
5. Appalakkal 
CONFIGURATION OF SEMEN 
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Based on siddha principles the  semen is constituent by eighty drops of blood which is 
equal to one drop of semen. Therefore wasting a drop of semen is equal to wasting six thousand 
four hundred drops of blood. 
―     
    
    
   !‖ 
    ---  -  – 1936 
 In the above verses states the significance of sperm. In modern correlation 
spermatogenesis the process by which the male gamete called spermatozoa are formed by 
various stages like proliferation, growth, maturation, transformation. 
SIGNIFICANCE OF SPERM 
      
      
     
   
      
  ” 
      -  
 After the penetration of the sperm in to the ovum the sperm head fuse with the oocyte to 
form single cell. Then it undergoes several stage of cell division and finally forms the embryo. 
“  
 
 
” 
       -  
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 The ovum consists of the element earth, whereas the sperm consist of fire and air. The 
uterine wall which nourishes it ling water and the urine cavity is of the element space. Therefore 
in the formation embryo of five elements combine and create it. 
―     
     
    
    !‖        - . 
 At the time of copulation, the semen is ejaculated. The prostatic fluid gives the semen a 
milky appearance. In the early minutes after ejaculation, the sperm remains immotile, possibly 
because of the viscosity of the coagulum. As the coagulum dissolves the sperm become highly 
motile. 
―     
    
    
   .     -  
 At the time of copulation if the male dominates then it is male & if the female dominates 
then it is a female child. If the male and the female are equal then the child will be neutral gender 
or a eunuch. Here male indicates the vindhu and the female indicates nadham. 
―     
  ‖        -  
 Abana stays outside of uterus and the prana goes along with spermatozoa and bisects the 
size of the zygote. 
―     
   
   
  ‖     -   
 The swadhittanam is to be found between the genital and navel region. The swadhittanam 
is correlated with adrenal gland which secretes testosterone. 
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―     
     
    
   ‖ 
     -   .1236---- 
 Sivavakiyaar in the above verses states that the sperm moves through the vagina in a 
tricky way and mixes with internal secretions and finally to form a ―DEW DROP‖. This dew 
drop enhances the growth of ovum. 
Modern correlation 
 Basic concepts of physiology states that the movement of the sperm through the uterus is 
facilitated by the anti peristaltic contractions of uterine muscles.among 200-300 millions of 
sperm entering female genital tract only a few thousands sperm reach the spot near ovum. 
Among these few thousands sperm only one succeeds in fertilizing the ovum. 
DIAGNOSIS OF DISEASE BY CHARACTERS OF SEMEN:  
1. White and akin to the butter, it is excellent. 
2. White and curd, it is very good. 
3. White and akin to the milk, it is good. 
4. White and akin to the buttermilk, it is fair. 
5. Akin to the honey in colour and consistency,it is average. 
6. Akin to the ghee in colour and weight, it is poor. 
7. Akin to the toddy in colour and thickness it is poor. 
8. Akin to the water, it is very bad. 
SIDDHA PATHOLOGY 
The subtle form of primordial elements  
1. Earth 
2. Water 
3. Fire 
4. Air 
5. Space 
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 In the above the Air element aggravates the urethral pain during purulent discharge from 
urethra. 
The properties of object having the five elemental components 
1. Earth - Bulk 
2. Water –Soft, giving pleasure, coolness soaking, viscid, slimy and flowing of semen. 
3. Fire -Hot 
4. Air - Denselessness 
5. Space – Sharp and clear 
The properties of taste 
 The ill effect caused by excessive intake of saltiest food leads to a gradual loss of vitality 
and vigor. The ill effect caused by excessive intake of pungent food leads to impotency. 
Based on Five Motor Organs 
1. Mouth 
2. Legs 
3. Hands 
4. Excretory Organs 
5. Reproductive Organs - Reproductive Organs causes Ejaculation, and ensures pleasure on 
account of reproduction. 
The Ten Channels (Dasa Naadi) 
1. Idakalai 
2. Pingalai 
3. Suzhimunai 
4. Siguvai 
5. Purudan  
6. Kanthari 
7. Aththi 
8. Alampudai 
9. Sangini 
10. Gugu. 
 Sangini – Located in Genital Organs. 
 Gugu – Located in Anorectal region. 
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The five kinds of Aasayams: 
1. Amarvasayam  
2. Pakirvasayam 
3. Salavasayam   
4. Malavasayam 
5. Sukkilavasayam – specified activities are semen secretion and storage. 
KOSAM (FIVE SHEATHS): 
1. Aanamaya kosam 
2. Pranamaya kosam 
3. Manomaya kosam –  constituted by the Mind and the Sense organs 
4. Vingnanamaya kosam 
5. Anaandhamaya Kosam – constituted by the Prana and Reproductive system 
EIGHT PASSIONS: 
1. Kaamam  
2. Kurotham  
3. Lopam  
4. Mokam  
5. Madham 
6. Maacharyam 
7. Idumbai 
8. Ahankaram   
*KAAMAM – Sexual desire 
THE THREE HUMOURS 
1. Vatham 
2. Pitham 
3. Kapham 
VATHAM- 10 different types: 
1. Pranan  
2. Abanan 
3. Vyanan 
4. Udhyanan 
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5. Samanan  
6. Nagan 
7. Koorman 
8. Kirukaran 
9. Devadhaththan 
10. Dhananjayan. 
 ABANAN – the downward Air. Responsible for excretion of urine, faeces and semen 
 VYANAN – activates the Voluntary and involuntary muscles. 
 DEVADATHTHAN – attributes human passions. 
PITHAM 5 different types: 
1. Analpasaka pitham 
2. Vanna eri 
3. Aarralankai 
4. Ulloli thee 
5. Nokkazhal  
 AARRALANKAI – improves Blood 
 ULLOLI THEE – gives color and brightness to the skin. 
KAPHAM – 5 different types: 
1. Ali aiyum 
2. Neerpi aiyum 
3. Suvaikaan aiyam 
4. niraivu aiyam 
5. Onri ayam 
 Seats of kabham- Urinary bladder, Genital organs which makes the urine and Semen 
come out of the body. 
SEVEN PHYSICAL CONSTITUTIONS  
1. Saarum (Chyle): This gives mental and physical perseverance. .  
2. Senneer (Blood): Imparts colour to the body, nourishes the body and is responsible for 
the Ally and intellect of an individual 
3. Oon (Muscle): It gives shape to the body according to the physical activity and covers 
bone.  
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4. Kozhuppu (Adipose tissue): it lubricates the joints and other parts of the body to 
function smoothly  
5. Enbu (Bone): Supports the frame and responsible for the postures and movements of 
body.  
6. Moolai (Bone marrow): It occupies the medulla of the bones and gives strength and 
softness to the muscles. 
7. Sukkilam (Sperm): It is responsible for reproduction. 
 Excess Sukilam causes love and lust towards women and urinary calculi. 
 Decreased sukkilam causes failure in reproduction, pain in the genitalia etc. 
FOURTEEN NATURAL URGES 
     Semen is the one of the fourteen urges 
―  
 
 
 
 
 
 
” 
     -  
  If Semen is controlled, it leads to fever,,oliguria, joint pain, urinary infection, 
spermatorrhoea, Leucorrhoea and chest pain. 
Significance of sperm implantation period: 
Implantation of sperm occurs few days before full moon leads to unhappiness. 
 Implantation of sperm occur six days after full moon leads to happiness 
 Four mugurthams before dawn is the right time to implantation of sperm 
 One mugurtham is equal to one and a half hour 
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.       -  
Symptoms associated with sukkilam 
In the above verses yugi muni states that 
1. Emaciation 
2. Constipation 
3. Oliguria 
4. Bleeding from the nose 
5. Phlegm accumulation due to increased kapham, breathlessness 
6. Loss of taste 
All the symptoms are associated with affected sukkilam. 
DIFFERNTIAL DIAGNOSIS: 
 
¸¡¡¢Â¡ö Á¢¸Å¡÷ò¨¾ §ÀÍõ §À¡Ð 
 ¸Øò¾¢ÖÇ ¿ÃõÒÁ¢¸ Å¢¨ºòÐ §¿¡Å¡õ 
Å¡¡¢Â¡ö Å¡÷ò¨¾¸û¾¡ý Å¢ì¸¢ô §Àº¢ 
 Å¡÷ò¨¾¸û¾¡ý   §ÀÍ Å¾¢ü ¦È¡¢ó¾¢ ¼¡Ð 
¿¡¡¢Â¡÷ §À¡¸ÁÐ Å¢ÕõÀ¢ ¼¡Ð 
 ¿Öì¸Á¡öò ¾¡Ð¦ÅÄ¡ Á¢¨ÇòÐì ¸¡Ïõ 
À¡¡¢Â¡ ÂÊì¸ÊìÌô Àº¢§Â Ôñ¼¡Ìõ 
 À¾¢¾Á¡õ Å¡¾¦Áý§È À¸Ã Ä¡§Á! 
       -ä¸¢ ÓÉ¢ Å¡¾ ¸¡Å¢Âõ 
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 Due to over talking more pain wil be felt neck aggravated in the cervical plexus. Loss of 
sexual,general weakness, increase appetite. 
                                
¬ñ¨ÁÂ¡í ¸¡§Ä¡Î ¨¸Ôï ºóÐ 
 «í¸ ¦ÁÄ¡ Á¢¸ò¾¢Á¢÷óÐ º¡½¢ ¾¡Ûõ 
âñ¨ÁÂ¡ô âº¢ÉÐ §À¡§Ä ¸¡Ïõ 
 ÒÃñÎ¾¡ý Å¢ÚÅ¢ÚòÐô ÒÇ¸ Á¡¸¢ô 
À¡ñ¨ÁÂ¡í ¸¡¾¨ºÔ Ó‰½Á¡¸¢ô 
 Àº¢òÐ§Á Á¢¸¿¡½¢ ¿¨¼ ¦¸¡¼¡Ð 
Å¡ñ¨ÁÂ¡õ Å¡ð¼ÓÚ ÁÂì¸ Á¡Ìõ 
 Å¡¾×À ¸¾ó¾ý¨É ÅÌò¾ Å¡§È! 
      -ä¸¢ ÓÉ¢ Å¡¾ ¸¡Å¢Âõ 
 Numbness of joints of upper and lower limbs,increased body heat,appetite,excessive 
tiredness and inability to walk, giddiness. 
LINE OF TREATMENT 
         In Siddha system the main aim of the treatment is to cure Udarpini (due to Mukkuttram) 
and Manapini (due to changes in Mukkunam). Treatment is not only for perfect healing but also 
for the prevention and rejuvenation. 
       It is essential to know the disease, the aetiology, the nature of the patient, severity of the 
illness, the seasons and the time of occurrence must be observed clearly. 
Line of treatment is as follows: 
1. Neekkam (Treatment) 
2. Niraivu (Rejuvenation) 
3. Kaapu (Prevention) 
 Thiruvalluvar describes the duty of the physician, i.e. study the disease, aetiology, seek 
subsiding ways and do what is proper and effective. 
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"§¿¡ö ¿¡Ê §¿¡ö Ó¾ø ¿¡Ê «Ð ¾½¢ìÌõ 
Å¡ö ¿¡Ê Å¡öôÀî ¦ºÂø" 
"¯üÈ¡ÉÇ×õ À¢½¢ÂÇ×í ¸¡ÄÓõ 
¸üÈ¡ý ¸Õ¾¢î ¦ºÂø" 
      - ¾¢ÕìÌÈû. 
1) NEEKKAM (Treatment in Siddha): 
 The aim of Neekkam is based on to bring the deranged Thodams to normal equilibrium 
state. 
 To treat the patient with internal medicine and external medicine 
  Siddha system of Medicine is based on Mukkutra Theory and hence the treatment is 
mainly aimed to bring the three thodams to equilibrium state and thereby restoring the 
physiological condition of the seven Thathus. 
 The three Thodams organise, regularise and integrate the body structure and their 
functions. They are always kept in a state of balance by thought, word, deed and food. Any 
imbalance will lead to disease. The imbalanced thodams are balanced by administrating 
purgatives or emetics or application of Anjanam (application on eyes) and followed by the 
appropriate systemic therapy by giving Siddha drugs.  
"Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ" 
"ÅÁÉò¾¡ø À¢ò¾õ ¾¡Øõ" 
"¿º¢Â «ïºÉò¾¡ø ¸Àõ ¾¡Øõ" - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
         Before treating with the trail drug the patients were advised to take oil bath with 
Arraku Thylam to normalize the vitiated pitham to equilibrium.
 The purgatives should be given before starting the trial to normalize the deranged 
Thodams to normal. 
 In this study the purgation is induced by giving Agasthiyar kulambu - 130 mg with hot 
water in early morning in empty stomach. 
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2) NIRAIVU (Rejuvenation): 
The word literally means the power of securing the body from the effect of age.According to 
Siddhars science rejuvenation does not necessarily mean restoring the old to youth for it may 
simply mean the maintenance of youth without reaching the old age. 
 So rejuvenation is a means for prolonging life & forms a part of immortality. 
       T.V. Sambasivam pillai dict. 
(Physical, psychological, social and economic rehabilitation and reassurance of 
Individuals are known as Niraivu). 
3. KAPPU (PREVENTION): 
The prevention methods for Aan Maladu are as follows: 
 Advised to take oil bath twice a week. 
 Advised to avoid smoking alcohol and using tobacco of any kind. 
 Advised to avoid sour rich food suffs.   
4) DIETARY RESTRICTIONS: 
 In siddha system of medicine the importance of dietary habits also emphasiszed for the 
diseases management and prevention. This line is well understood in these verses, 
“¯½§Å ÁÕóÐ ÁÕó§¾ ¯½×”. 
“ÁÕó¦¾É §Åñ¼¡Å¡õ Â¡ì¨¸ìÌ «Õó¾¢ÂÐ 
«üÈÐ §À¡üÈ¢ ¯½¢ý”.              - ¾¢ÕìÌÈû 
In diseased condition diet restrictions or paththiyam are strictly followed to increase the 
effectiveness of medicine, and to reducing the severity of diseases. This is given in the following 
verse, 
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“Àò¾¢Âò¾¢É¡§Ä ÀÄý ¯ñ¼¡Ìõ ÁÕóÐ 
Àò¾¢Âí¸û §À¡É¡ø ÀÄý§À¡Ìõ - Àò¾¢Âò¾¢ø 
Àò¾¢Â§Á ¦ÅüÈ¢¾Õõ ÀñÊ¾÷ìÌ ¬¾Ä¢É¡ø 
Àò¾¢Â§Á ¯ò¾¢¦ÂýÚ À¡÷”    - §¾¨ÃÂ÷ ¦ÅñÀ¡. 
þîº¡ Àò¾¢Âò¾¢ø ¿£ìÌõ ¦À¡Õð¸û: 
"¸ÎÌ ¿üÈ¢Äò ¦¾ñ¨½ö ÜúÀ¡ñ¼í¸û ¸¼¨Ä 
ÅÕÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸ ¿ü¸¡Âõ 
ÁÊÅ¢Ä¡¾ ¦ÅûÙûÇ¢¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ 
þ¼Ú À¡¸§Ä¡ ¼¸ò¾¢ ¿£ì¸¢¼Ä¢îº¡ Àò¾¢Âõ" 
     - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
¸ÎÌ, ±û¦¿ö, ¸øÂ¡½âº½¢ì¸¡ö, ¸û, ¸¼¨Ä, §¾í¸¡ö, Á¡í¸¡ö, ÀÄ¡, ¸¡Âõ, 
¯ûÇ¢ôâñÎ, ¦¸¡û, Ò¨¸Â¢¨Ä, ¦Àñ¸û §º÷ì¨¸, À¡¸ø, «¸ò¾¢ þ¨Å¸¨Ç þîº¡ 
Àò¾¢Âò¾¢ø ¿£ì¸ §ÅñÎõ. 
"ÒÇ¢ÐÅ÷ Å¢ïÍõ ¸È¢Â¡ø âÃ¢ìÌõ Å¡¾õ" 
      - §¿¡ö ¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø ¾¢ÃðÎ 
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THE MALE REPRODUCTIVE SYSTEM 
 
Male Reproductive System 
 
 
 
 
 
The purpose of the organs of the male reproductive system is to perform the following functions: 
• To produce, maintain, and transport sperm (the male reproductive cells) and protective 
fluid (semen) 
• To discharge sperm within the female reproductive tract during sex 
• To produce and secrete male sex hormones responsible for maintaining the male 
reproductive system 
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Unlike the female reproductive system, most of the male reproductive system is located outside 
of the body. These external structures include the penis, scrotum, and testicles. 
• Penis: This is the male organ used in sexual intercourse. It has three parts: the root, which 
attaches to the wall of the abdomen; the body, or shaft; and the glans, which is the cone-shaped 
part at the end of the penis. The glans, also called the head of the penis, is covered with a loose 
layer of skin called foreskin. This skin is sometimes removed in a procedure called circumcision. 
The opening of the urethra, the tube that transports semen and urine, is at the tip of the penis. The 
penis also contains a number of sensitive nerve endings. 
 
The body of the penis is cylindrical in shape and consists of three circular shaped chambers. 
These chambers are made up of special, sponge-like tissue. This tissue contains thousands of 
large spaces that fill with blood when the man is sexually aroused. As the penis fills with blood, 
it becomes rigid and erect, which allows for penetration during sexual intercourse. The skin of 
the penis is loose and elastic to accommodate changes in penis size during an erection. 
• The internal organs of the male reproductive system, are called as accessory organs 
which includes the following: 
• Epididymis: The epididymis is a long, coiled tube that rests on the backside of each 
testicle. It transports and stores sperm cells that are produced in the testes. It is the job of the 
epididymis to bring the sperm in to maturity, since the sperms that emerge from the testes are 
immature and incapable of fertilization. During sexual arousal, contractions force the sperm into 
the vas deferens. 
• Vas deferens: The vas deferens is a long, muscular tube that travels from the epididymis 
into the pelvic cavity, to just behind the bladder. The vas deferens transports mature sperm to the 
urethra, the tube that carries urine or sperm to outside of the body, in preparation for ejaculation. 
• Ejaculatory ducts: These are formed by the fusion of the vas deferens and the seminal 
vesicles (see below). The ejaculatory ducts empty into the urethra. 
• Urethra: The urethra is the tube that carries urine from the bladder to outside of the 
body. In males, it has the additional function of ejaculating semen when the man reaches orgasm. 
When the penis is erect during sex, the flow of urine is blocked from the urethra, allowing only 
semen to be ejaculated at orgasm. 
• Seminal vesicles: The seminal vesicles are sac-like pouches that attach to the vas 
deferens near the base of the bladder. The seminal vesicles produce a sugar-rich fluid (fructose) 
that provides sperm with a source of energy to help them move. The fluid of the seminal vesicles 
makes up most of the volume of a man's ejaculatory fluid, or ejaculate. 
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• Prostate gland: The prostate gland is a walnut-sized structure that is located below the 
urinary bladder in front of the rectum. The prostate gland contributes additional fluid to the 
ejaculate. Prostate fluids also help to nourish the sperm. The urethra, which carries the ejaculate 
to be expelled during orgasm, runs through the center of the prostate gland. 
• Bulbourethral glands: Also called Cowper's glands, these are pea-sized structures 
located on the sides of the urethra just below the prostate gland. These glands produce a clear, 
slippery fluid that empties directly into the urethra. This fluid serves to lubricate the urethra and 
to neutralize any acidity that may be present due to residual drops of urine in the urethra. 
Function of the Male Reproductive System  
The entire male reproductive system is dependent on hormones, which are chemicals that 
regulate the activity of many different types of cells or organs. The primary hormones involved 
in the male reproductive system are follicle-stimulating hormone, luteinizing hormone, and 
testosterone. 
Follicle-stimulating hormone is necessary for sperm production (spermatogenesis), and 
luteinizing hormone stimulates the production of testosterone, which is also needed to make 
sperm. Testosterone is responsible for the development of male characteristics, including muscle 
mass and strength, fat distribution, bone mass, facial hair growth, voice change, and sex drive. 
Semen, which contains sperm (reproductive cells), is expelled (ejaculated) through the end of the 
penis when the man reaches sexual climax (orgasm). When the penis is erect, the flow of urine is 
blocked from the urethra, allowing only semen to be ejaculated at orgasm. 
• Scrotum: This is the loose pouch-like sac of skin that hangs behind and below the penis. 
It contains the testicles (also called testes), as well as many nerves and blood vessels. The 
scrotum acts as a "climate control system" for the testes. For normal sperm development, the 
testes must be at a temperature slightly cooler than body temperature. Special muscles in the wall 
of the scrotum allow it to contract and relax, moving the testicles closer to the body for warmth 
or farther away from the body to cool the temperature. 
• Testicles (testes): These are oval organs about the size of large olives that lie in the 
scrotum, secured at either end by a structure called the spermatic cord. Most men have two 
testes. The testes are responsible for making testosterone, the primary male sex hormone, and for 
generating sperm. Within the testes are coiled masses of tubes called seminiferous tubules. These 
tubes are responsible for producing sperm cells. 
Sperm 
• Sperm are made in hundreds of microscopic tubes, known as seminiferous tubules, which 
make up most of the  testicles. 
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Surrounding these tubules are clumps of tissue containing Leydig cells, which produce 
testosterone when stimulated by luteinizing hormone (LH). 
• Sperm Development. The life cycle of sperm takes about 74 days: 
• Sperm in the begining partially embedded in nurturing Sertoli cells, which are located in 
the lower parts of the seminiferous tubules. 
• As they mature  move along,and are stored in the upper part of the seminiferous tubules. 
Young sperm cells are known as spermatids. 
• When the sperm has completed the development of its head and tail, it is released from 
the cell into the epididymis. This C-shaped tube is 1/300 of an inch in diameter and about 20 feet 
long. It loops back and forth on itself within a space that is only about one and a half inches long. 
The sperm's journey through the epididymis takes about 3 weeks. 
 The fluid in which the sperm is transported contains sugar in the form of fructose, which 
provides energy as the sperm matures. In the early stages of its passage, the sperm cannot swim 
in a forward direction and can only vibrate its tail weakly. By the time the sperm reaches the end 
of the epididymis, however, it  mature and looks like a microscopic squirming tadpole. 
 At maturity, each healthy sperm consists of a head that contains the man's genetic 
material (his DNA) and a tail that lashes back and forth at great speed to propel the head forward 
at about four times its own length every second. The ability of a sperm to move forward rapidly 
and straight is probably the most significant determinant of male fertility. 
 Ejaculation. When a man experiences sexual excitement, nerves stimulate the muscles in 
the epididymis to contract, which forces the sperm out through the penis: 
 After being produced in the testicle, the sperm first pass through the epididymis and then 
into one of two rigid and wire-like muscular channels, called the vasa deferentia. (A single 
member of this pair of channels is called a vas deferens.) 
 Muscle contractions in the vas deferens from sexual activity propel the sperm along past 
the seminal vesicles. These are clusters of tissue that contribute fluid, called seminal fluid, to the 
sperm. The vas deferens also collects fluid from the nearby prostate gland. This mixture of 
various fluids and sperm is the semen. 
 Each vas deferens then joins together to form the ejaculatory duct. This duct, which now 
contains the sperm-containing semen, passes down through the urethra. (The urethra is the same 
channel in the penis through which a man urinates, but during orgasm, muscles close off the 
bladder so that urine cannot enter the urethra.) 
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 The semen is forced through the urethra during ejaculation, the final stage of orgasm 
when the sperm is literally shot out of the penis. 
. 
Sperm Abnormalities 
Sperm abnormalities can be caused by a range of factors, including congenital birth defects, 
disease, chemical exposure, and lifestyle habits. In many cases,the causes of sperm abnormalities 
are unknown. 
Sperm abnormalities are categorized by whether they affect sperm count, sperm movement, or 
sperm shape. They include: 
 
• Low Sperm Count (Oligospermia). sperm count of less than 20 million/mL is 
considered as Azoospermia refers to the complete absence of sperm cells in the ejaculate. Partial 
obstruction anywhere in the long passages through which sperm pass can reduce sperm counts. 
Sperm count varies widely over time, and temporary low counts are common. A single test that 
reports a low count may not be a representative result. 
 
• Poor Sperm Motility (Asthenospermia). Sperm motility is the sperm's ability to move. 
If movement is slow or not in a straight line, the sperm have difficulty invading the cervical 
mucus or penetrating the hard outer shell of the egg. If 60% or more of sperm have normal 
motility, the sperm is said to be average in quality. If less than 40% of sperm are able to move in 
a straight line, the condition is considered abnormal. Sperm that move sluggishly may have 
genetic or other defects that render them incapable of fertilizing the egg. Poor sperm motility 
may be associated with DNA fragmentation and may increase the risk for passing on genetic 
diseases. 
 
• Abnormal Sperm Morphology (Teratospermia). Morphology refers to shape and 
structure. Abnormally shaped sperm cannot fertilize an egg. About 60% of the sperm should be 
normal in size and shape for adequate fertility. The perfect sperm structure is an oval head and 
long tail. 
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 In addition to providing the fluid that transports the sperm, semen also has other benefits: 
• It provides a very short-lived alkaline environment to protect sperm from the harsh 
acidity of the female vagina. (If the sperm do not reach the woman's cervix within several hours, 
the semen itself becomes toxic to sperm and they die.) 
• It contains a gelatin-like substance that prevents it from draining from the vagina too 
quickly. 
• It contains sugar in the form of fructose to provide instant energy for sperm locomotion. 
• The sperm's passage to the egg is a difficult journey.Semen provides the pathway for the 
sperm to reach the egg. 
• Usually about 100 - 300 million sperm are delivered into the ejaculate at any given time. 
Even under normal conditions only about 15% of these millions of sperm are strong enough to 
fertilize an egg. 
• After the stress of ejaculation, only about 400 sperm survive the orgasm to continue the 
journey. 
• Out of this number, only about 40 sperm survive the challenges posed by the semen and 
the environment of the vagina to reach the vicinity of the egg. Normally, the cervical mucus 
forms an impenetrable barrier to sperm. However, when a woman ovulates (releases her egg, the 
oocyte), the mucous lining thins to allow sperm penetration. 
• Sperm that manage to reach the mucus lining in the woman's cervix (the lower part of her 
uterus) must survive about four more days to reach the woman's fallopian tubes. (Here, the egg is 
positioned for fertilization for only 12 hours each month.) 
• The few remaining sperm that penetrate the cervical mucus and are able to reach the 
fallopian tubes become capacitated. 
• Capacitation is a one-time explosion of energy that completes the sperm's journey. It 
boosts the motion of the sperm and triggers the actions of the acrosome, a membrane that covers 
the head of the sperm and resembles a warhead. The acrosome is dissolved, and enzymes 
contained within it are released to allow the sperm to drill a hole through the tough outer coating 
of the egg. 
• In the end, only one sperm gets through to fertilize the egg 
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Testosterone 
 A testosterone test checks the level of this male hormone (androgen) in the 
blood.Testosterone affects sexual features and development. In men, it is made in large amounts 
by the testicles. In both men and women, testosterone is made in small amounts by the adrenal 
glands; and, in women, by the ovaries. 
 The pituitary gland controls the level of testosterone in the body. When the testosterone 
level is low, the pituitary gland releases a hormone called luteinizing hormone (LH). This 
hormone tells the testicles to make more testosterone. See a picture of the pituitary gland . 
 Before puberty, the testosterone level in boys is normally low. Testosterone increases 
during puberty. This causes boys to develop a deeper voice, get bigger muscles, make sperm, and 
get facial and body hair. The level of testosterone is the highest around age 40, then gradually 
becomes less in older men. 
 In women, the ovaries account for half of the testosterone in the body. Women have a 
much smaller amount of testosterone in their bodies compared to men. But testosterone plays an 
important role throughout the body in both men and women. It affects the brain, bone and muscle 
mass, fat distribution, the vascular system, energy levels, genital tissues, and sexual functioning. 
 Most of the testosterone in the blood is bound to a protein called sex hormone binding 
globulin (SHBG). Testosterone that is not bound ("free") can also be checked if a man or a 
woman is having sexual problems. 
Significance of testosterone: 
• A low amount of testosterone can lead to low sperm counts. 
• . A low level of testosterone may lower a man's sex drive or not allow him to have 
an erection (erectile dysfunction). 
• See whether a high level of testosterone is causing a boy younger than age 10 to 
have early signs of puberty. 
• Check a decreased sex drive in a woman. This may be due to the level of 
testosterone in her body. 
• Find out why a woman is developing male features, such as excessive facial and 
body hair (hirsutism) and a deep voice. 
• Find out why a woman is having irregular menstrual periods. 
• See if testosterone-lowering medicines are working in a man with 
advancedprostate cancer. 
• Find the cause of osteoporosis in a man. 
A testosterone test checks the level of  androgen(male sex hormone) in the blood. 
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Normal 
The normal values listed here-called a reference range-are just a guide. These ranges vary from 
lab to lab, and your lab may have a different range for what’s normal.  
Table : 1 
Total testosterone 
Men 270-1070 ng/dL (9-38 nmol/L) 
Women 15-70 ng/dL (0.52-2.4 nmol/L) 
Children 2-20 ng/dL or 0.07-0.7 nmol/L 
 
The testosterone level for a postmenopausal woman is about half the normal level for a healthy, 
nonpregnant woman. And a pregnant woman will have 3 to 4 times the amount of testosterone 
compared to a healthy, nonpregnant woman. 
Table : 2 
Free testosterone 
Men 50-210 pg/mL (174-729 pmol/L) 
Women 1.0-8.5 pg/mL (3.5-29.5 pmol/L) 
 The etiologic factors in male infertility continue to be debated and there is incomplete 
knowledge about its pathophysiology.  
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 A varicocele develops when the one way valves in these spermatic veins are damaged 
causing an abnormal back flow of blood from the abdomen into the scrotum creating a hostile 
environment for sperm development.  Varicocoeles may cause reduced sperm count and 
abnormal sperm morphology which cause infertility.  Variococles can usually be diagnosed by a 
physical examination of the scrotum which can be aided by the Doppler stethoscope and scrotal 
ultrasound.  Varicocoele can be treated in many ways but the most successful treatments involve 
corrective surgery. 
INVESTIGATION 
1.Semen sample 
 A semen sample is collected by masturbation. Patient is adviced to urinate and then wash 
and rinse their hands and penis before collecting the semen in a sterile cup. Lubricants or 
condoms should not be used when collecting the sample. While collect the semen sample at 
home, be sure to get it to the lab or clinic within 1 hour. Keep the sample at body temperature 
and out of direct sunlight. The sample cannot be collected by having sexual intercourse and then 
withdrawing when you ejaculate because vaginal fluid may be mixed with the sperm. 
2.Collection of Semen 
 Patient was asked to avoid any sexual activity that results in ejaculation for 2 to 5 days 
before a semen analysis. This helps to ensure that sperm count will be at its highest, and it 
improves the reliability of the test. If possible, do not avoid sexual activity for more than 1 to 2 
weeks before this test, because a long period of sexual inactivity can result in less active sperm. 
Patient was asked to avoid drinking alcohol for a few days before the test. 
• The most common way to collect semen is by masturbation, directing the semen into a 
clean sample cup. Do not use a lubricant. 
• Patient was advised to collect a semen sample during sex by withdrawing their penis 
from their partner just before ejaculating (coitus interruptus). patient then ejaculate into a clean 
sample cup. This method can be used after a vasectomy to test for the presence of sperm, but 
other methods will likely be recommended if you are testing for infertility. 
Sperm collection by surgical method:  
  If sperm cannot be collected by means of masturbation, they are surgically removed from 
a testicle through a small incision. This method of sperm retrieval is done when there is a 
blockage that prevents sperm from being ejaculated or when there is a problem with sperm 
development. To screen for possible genetic problems that could affect offspring, experts 
recommend that men with little or no sperm in their semen (not due to a blockage) have genetic 
testing before they proceed with ICSI. 
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3. Sperm Penetration Tests 
 Sperm penetration tests were check carried out to whether a man's sperm can move 
through cervical mucus and the fallopian tubes to join with (fertilize) an egg. This test is usually 
done when a couple is having trouble becoming pregnant (infertility). 
SEMEN ANALYSIS 
• Volume. This is a measure of how much semen is present in one ejaculation. 
• Liquefaction time. Semen is a thick gel at the time of ejaculation and normally becomes 
liquid within 20 minutes after ejaculation. Liquefaction time is a measure of the time taken by 
the semen to liquefy. 
• Sperm count. This is a count of the number of sperm present per milliliter (mL)of semen 
in one ejaculation. 
• Sperm morphology. This is a measure of the percentage of sperm that have a normal 
shape. 
• Sperm motility. This is a measure of the percentage of sperm that can move forward 
normally. The number of sperm that show normal forward movement in a certain amount of 
semen can also be measured (motile density). 
• pH. This is a measure of the acidity (low pH) or alkalinity (high pH) of the semen. 
• White blood cell count. White blood cells are not normally present in semen. 
• Fructose level. This is a measure of the amount of a sugar called fructose in the semen. 
The fructose provides energy for the sperm 
Significance of Semen Analysis: 
A semen analysis is done to determine whether: 
• A man has a reproductive problem that is causing infertility. 
• A vasectomy has been successful. 
• The reversal of a vasectomy has been successful. 
Intracytoplasmic Sperm Injection for Infertility 
Intracytoplasmic sperm injection (ICSI) is an assisted reproductive technology (ART) used to 
treat sperm-related infertility problems. ICSI is used to enhance the fertilization phase of in vitro 
fertilization (IVF) by injecting a single sperm into a mature egg. The fertilized egg is then placed 
in a woman's uterus or fallopian tube. 
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4.Antisperm Antibody Test 
 An antisperm antibody test looks for special proteins (antibodies) that fight against a 
man's sperm in blood, vaginal fluids, or semen. The test uses a sample of sperm and adds a 
substance that binds only to affected sperm. 
Semen can cause an immune system response in either the man's or woman's body. The 
antibodies can damage or kill sperm. If a high number of sperm antibodies come into contact 
with a man's sperm, it may be hard for the sperm to fertilize an egg. The couple has a hard time 
becoming pregnant. This is called immunologic infertility. 
A man can make sperm antibodies when his sperm come into contact with his immune system. 
This can happen when the testicles are injured or after surgeries (such as a biopsy or vasectomy) 
or after a prostate gland infection. The testicles normally keep the sperm away from the rest of 
the body and the immune system. 
A woman can have an allergic reaction to her partner's semen and make sperm antibodies. This 
kind of immune response is not fully understood but may affect fertility. This is a rare cause of 
infertility. 
Significance of Antisperm antibody test 
The antisperm antibody test may be done if: 
• A cause for infertility cannot be found. Experts disagree about the usefulness of the test 
because the result may not change the treatment. 
• The results from another fertility test, such as the postcoital test, are not clear. 
• An antisperm antibody test looks for special proteins (antibodies) that fight against a 
man's sperm in blood, vaginal fluids, or semen. The higher the level of antibody-affected sperm 
found in the semen, the lower the chance of the sperm fertilizing an egg. 
Medical causes for Male infertility 
 Problems with male fertility can be caused by a number of health issues and medical 
treatments. More than 90% of male infertility cases are due to low sperm counts, poor sperm 
quality, or both. The remaining cases of male infertility can be caused by a number of factors 
including anatomical problems, hormonal imbalances, and genetic defects 
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 Varicocele: A varicocele is a swelling of the veins that drain the testicle. It's a common 
cause of male infertility. This may prevent normal cooling of the testicle, leading to reduced 
sperm count and fewer moving sperm. 
 Infection: Some infections can interfere with sperm production or sperm health, or can 
cause scarring that blocks the passage of sperm. These include some sexually transmitted 
infections, including chlamydia and gonorrhea; inflammation of the prostate (prostatitis); and 
inflamed testicles due to mumps (mumps orchitis). 
 Ejaculation issues: Retrograde ejaculation occurs when semen enters the bladder during 
orgasm instead of emerging out the tip of the penis. Various health conditions can cause 
retrograde ejaculation, including diabetes, spinal injuries, medications, and surgery of the 
bladder, prostate or urethra. Some men with spinal cord injuries or certain diseases can't ejaculate 
semen, even though they still produce sperm. 
 Antibodies that attack sperm: Anti-sperm antibodies are immune system cells that 
mistakenly identify sperm as harmful invaders and attempt to eliminate them. 
 Tumors: Cancers and nonmalignant tumors can affect the male reproductive organs 
directly or can affect the glands that release hormones related to reproduction, such as the 
pituitary gland. In some cases, surgery, radiation or chemotherapy to treat tumors can affect male 
fertility. 
 Undescended testicles: In some males, during fetal development one or both testicles fail 
to descend from the abdomen into the sac that normally contains the testicles (scrotum). 
Decreased fertility is more likely in men who have had this condition. 
 Hormone imbalances: Infertility can result from disorders of the testicles themselves or 
an abnormality affecting other hormonal systems including the hypothalamus, pituitary, thyroid 
and adrenal glands. Low testosterone (male hypogonadism) and other hormonal problems have a 
number of possible underlying causes. 
 Sperm duct defects: The tubes that carry sperm (sperm ducts) can be damaged by illness 
or injury. Some men experience blockage in the part of the testicle that stores sperm (epididymis) 
or a blockage of one or both of the tubes that carry sperm out of the testicles. Men with cystic 
fibrosis and some other inherited conditions may be born without sperm ducts altogether. 
 Chromosome defects: Inherited disorders such as Klinefelter's syndrome — in which a 
male is born with two X chromosomes and one Y chromosome (instead of one X and one Y) — 
cause abnormal development of the male reproductive organs. Other genetic syndromes 
associated with infertility include cystic fibrosis, Kallmann's syndrome, Young's syndrome and 
Kartagener syndrome. 
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 Problems with sexual intercourse: These can include trouble keeping or maintaining an 
erection sufficient for sex (erectile dysfunction), premature ejaculation, painful intercourse, 
anatomical abnormalities such as having a urethral opening beneath the penis (hypospadias), or 
psychological or relationship problems that interfere with sex. 
 Celiac disease: A digestive disorder caused by sensitivity to gluten, celiac disease can 
cause male infertility. Fertility may improve after adopting a gluten-free diet. 
 Certain medications: Testosterone replacement therapy, long-term anabolic steroid use, 
cancer medications (chemotherapy), certain antifungal medications, some ulcer drugs and certain 
other medications can impair sperm production and decrease male fertility. 
Environmental causes 
 Over exposure to certain environmental elements such as heat, toxins and chemicals can      
reduce sperm production or sperm function. Specific causes include: 
• Industrial chemicals: Extended exposure to benzenes, toluene, xylene, pesticides, 
herbicides, organic solvents, painting materials and lead may contribute to low sperm counts. 
• Heavy metal exposure: Exposure to lead or other heavy metals also may cause 
infertility. 
• Radiation or X-rays: Exposure to radiation can reduce sperm production, though it will 
often eventually return to normal. With high doses of radiation, sperm production can be 
permanently reduced. 
• Exposure to heat: Frequent use of saunas or hot tubs may temporarily lower your sperm 
count. Sitting for long periods, wearing tight clothing or working on a laptop computer for long 
stretches of time also may increase the temperature in your scrotum and slightly reduce sperm 
production. The type of underwear you wear is unlikely to make a significant difference in male 
fertility 
HEALTH, LIFESTYLE AND OTHER CAUSES 
Some other causes of male infertility include: 
• Illegal drug use: Anabolic steroids taken to stimulate muscle strength and growth can 
cause the testicles to shrink and sperm production to decrease. Use of cocaine or marijuana may 
temporarily reduce the number and quality of your sperm as well. 
• Alcohol use: Drinking alcohol can lower testosterone levels, cause erectile dysfunction 
and decrease sperm production. Liver disease caused by excessive drinking also may lead to 
fertility problems. 
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• Occupation: Certain occupations can increase your risk of infertility, including those 
associated with extended use of computers or video display monitors, shift work, and work-
related stress. 
• Tobacco smoking: Men who smoke may have a lower sperm count than do those who 
don't smoke. Secondhand smoke also may affect male fertility. 
• Emotional stress: Stress can interfere with certain hormones needed to produce sperm. 
Severe or prolonged emotional stress, including problems with fertility, can affect your sperm 
count. 
• Weight: Obesity can cause hormone changes that reduce male fertility. 
Prolonged bicycling: Prolonged bicycling is another possible cause of reduced fertility due to 
overheating the testicles. In some cases, bicycle seat pressure on the area behind the testicles 
(perineum) can cause numbness in the penis and erectile hormonal deficiencies. 
Hypogonadism is the general name for a severe deficiency in gonadotropin-releasing hormone 
(GnRH), the primary hormone that signals the process leading to the release of testosterone and 
other important reproductive hormones. Low levels of testosterone from any cause may result in 
defective sperm production. 
PSYCHOLOGICAL/PHYSICAL/BEHAVIORAL PROBLEMS 
Several sexual problems both psychological and physical in nature.  it is difficult to separate the 
physiological and physical components exist that can affect male fertility.    
Erectiledysfunction(ED):   
   ED is the result of a single, or more commonly a combination of multiple factors.  In the 
past, ED was thought to be the result of psychological problems, but new research indicates that 
90 percent of cases are organic in nature.  However, most men who suffer from ED have a 
secondary psychological problem that can worsen the situation like performance anxiety, guilt, 
and low self-esteem.   
common causes of impotence include: diabetes, high blood pressure, heart and vascular 
disease, stress, hormone problems, pelvic surgery, trauma, venous leak. 
Premature Ejaculation:  
 Is defined as an inability to control the ejaculatory response for at least thirty seconds 
following penetration.  Premature ejaculation becomes a fertility problem when ejaculation 
occurs before a man is able to fully insert his penis into his partner’s vagina.  Premature 
ejaculation can be overcome by artificial insemination or by using a behavioral modification 
technique called the ―squeeze technique‖ which desensitizes the penis. 
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Ejaculatory Incompetence:  
 This rare psychological condition prevents men from ejaculating during sexual 
intercourse even though they can ejaculate normally through masturbation.  This condition 
sometimes responds well to behavioral therapy; if this technique does not work, artificial 
insemination can be employed using an ejaculate from masturbation. 
RISK FACTORS REGARDING MALE INFERTILITY 
A number of risk factors are linked to male infertility. They include: 
• Smoking tobacco 
• Using alcohol 
• Using certain illegal drugs 
• Being overweight 
• Having certain past or present infections 
• Being exposed to toxins 
• Overheating the testicles 
• Having a prior vasectomy or vasectomy reversal 
• Being born with a fertility disorder or having a blood relative with a fertility disorder 
• Having certain medical conditions, including tumors and chronic illnesses 
• Taking certain medications or undergoing medical treatments, such surgery or radiation 
used for treating cancer 
• Performing certain prolonged activities such as bicycling or horseback riding, especially 
on a hard seat or poorly adjusted bicycle 
Complications of Male infertility 
Infertility can be stressful for both you and your partner. Complications can include: 
• Surgery or other procedures to treat an underlying cause of low sperm count or other 
reproductive problems 
• Expensive and involved reproductive techniques such as in vitro fertilization 
• Stress and relationship difficulties related to the inability to have a child 
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LIFESTYLE CHANGES 
Timing and Monitoring Sexual Activity for Best Results  
Both male and female hormone levels fluctuate according to the time of day, and they also vary 
from day to day and month to month. Some timing tips might be helpful. 
 Fertility and Seasonal Changes. Some studies have reported higher sperm counts in the 
winter than in the summer. For women, fertility rates as measured by treatment success are 
highest in months when days are longest. 
 Monitoring Basal Body Temperature. To determine the most likely time of ovulation 
and therefore the time of fertility, a woman should take her body temperature, called her basal 
body temperature. This is the body's temperature as it rises and falls in accord with hormonal 
fluctuations. 
 By studying the temperature patterns after a few months, couples can begin to anticipate 
ovulation and plan their sexual activity accordingly. 
 Frequency of Intercourse. It is not clear how often a couple should have intercourse in 
order to conceive. Some doctors think that having sex more than 2 days a week adds no benefits. 
In addition, frequent sexual activity lowers sperm count per ejaculation. Some studies have 
indicated, however, that having intercourse every day, or even several times a day, before and 
during ovulation, improves pregnancy rates. Although sperm count per ejaculation is low, a 
constantly replenished semen supply is more likely to result in a fertilized egg. 
 Dietary Considerations: Everyone should eat a healthy diet rich in fresh fruits, 
vegetables, and whole grains. Replace animal fats with monounsaturated oils, such as olive oil. 
Certain specific nutrients and vitamins have been studied for their effects on male infertility and 
sperm health. They include antioxidant vitamins (vitamin C, vitamin E) and the dietary 
supplements L-carnitine and L-acetylcarnitine. To date, there is no conclusive evidence that they 
are effective. 
NUTRITIONAL CONSIDERATIONS 
Vitamin c and other Anti- oxidants 
 Free radical or oxidative damage to sperm is thought to be responsible for many cases of 
idiopathic oligospermia, with high levels of free radicals found in the semen of 40% infertile 
men. Three factors combine to render sperm particularly susceptible to free radical damage. 
    A high membrane concentration of polysaturated fatty acids 
    Active generation of free radicals 
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 A lack of defensive enzymes. 
                The health of the sperm critically dependent upon antioxidants. Although most free 
radicals are produced during normal metabolic processes, the environment contributes greatly to 
the free radical load. Men exposed to increased levels of source of free radicals are much more 
likely to have abnormal sperm and sperm counts. 
 Sperm extremely sensitive to free radicals because they are so dependent upon the 
integrity and fluidity of their cell membrane for proper function. Without proper membrane 
fluidity, enzymes are activated, which can lead to impaired motility, abnormal structure loss of 
viability and ultimately death of sperm. The major determinant of membrane fluidity is the 
concentration of polyunsaturated fatty acids, particularly omega-3 fatty acids which are very 
susceptible to free radical damage. The sperm have a relative  lack of super oxide dismutase and 
catalase which can prevent oxidative damage. 
 A common source of oxide is cigarette smoking, which is associated with decreased 
sperm counts and sperm motility as well as increased frequency of abnormal sperm. Increase in 
environmental pollution, is thought to be a major contributor to the decreased in sperm counts 
seen in many industrialized nations. Anti oxidants such as vitamin C, beta carotene, selenium 
and vitamin E have been shown to be very important in protecting sperm against damage. 
Vitamin C plays an vital role in protecting the sperm’s genetic material (DNA) from damage. 
Ascorbic acid levels are much higher in seminal fluid compared with other body fluids. When  
when dietary vitamin C was reduced from 250 to 5mg/ day in healty human subjects, the seminal 
fluid ascorbic acid decreased by 50% and the number of sperm with damage of DNA increased 
by 91%. 
 It is well documented that cigarette smoking greatly reduces vitamin C levels throughout 
the body. Vitamin E has been shown to play an essential role in inhibiting free radical damage to 
the unsaturated fatty acids of the sperm membrane. Vitamin E enhances the ability of sperm to 
fertilize an egg in test tubes. 
Fats and oils  
 Saturated fats, hydrogenated oils, trans-fatty acids, cotton seed, coconut and palm oil 
should be avoided. Coconut and palm oils are primarily saturated fat, while cotton seed may 
contain toxic residues, due to heavy spraying of cotton and its high levels of gossypol, a 
substance known to inhibit the sperm function. Infact, gossypol is being investigated as the ― 
male birth control pill‖. Its use as an antifertility agent began after studies demonstrated that men 
who had used crude cotton seed oil as their cooking oil were shown to have low sperm counts 
followed by total testicular failure. Excessive consumption of saturated fats combined with 
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inadequate intake of essential fatty acids changes the fatty acid composition of sperm 
membranes, thus decreasing fluidity and interfering with sperm motility.  
 The patient must be informed to read food labels carefully and avoid all sources of cotton 
seed oil and other damaging oils. While the in take of saturated and hydrogenated fats must be 
eliminated , the intake of polyunsaturated oils should be increased. These oils function in all 
aspects of sexual function including sperm formation and activity much lower  in infertile men 
with low sperm counts, including that a low zinc status may be the contributing factor to the 
infertility. Zinc is found in whole grains, legumes, nuts and seeds. 
Vitamin B12 
 Vitamin B12 is involved in cellular replication. A deficiency of vitamin B12 leads to 
reduced sperm counts and sperm motility.  
Arginine  
 The amino acids arginine is required for the replication of cells, making it essential in 
sperm formation.  
Carnitine 
 Carnitine is essential in the transport of  fatty acids in to the mitochondria. A deficiency 
of carnitine results in a decrease in fatty acid concentrations in the mitochondria and reduced 
energy production. Carnitine concentrations are extremely high in the epididymis and sperm , 
suggesting a role for carnitine in male reproductive function. The epididymis derives the 
majority of its  energy requirements from fatty acids, as do the sperm, during transport through 
the epididymis . after the ejaculation, the motility of sperm correlates directly with carnitine 
content.  
 The higher the carnitine content , the more motile are the sperm. Supplementing the diet 
with L- carnitine may be useful in restoring male fertility. 
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STANDARD OPERATING PROCEDURE OF THE TRIAL DRUG 
POONAIKALI VITHAI CHOORANAM 
 
SOURCE OF RAW DRUGS:  
           The required raw drugs for the preparation of    Poonaikali Vithai chooranam  will be  
purchased from a well reputed country shop. The raw drugs  will be authenticated by the 
Asst.Prof of medicinal botany at NIS. Then the raw drugs will be purified as mentioned  in 
siddha literature. The medicine is prepared in Gunapadam lab of National Institute of Siddha. 
 
REQUIRED RAW DRUGS: 
1. Poonaikali vithai(Mucuna pruriens, Linn Dc) 
2. Siru nerunjil vithai (Tribulus terrestris,Linn) 
3. Thanneer vittan kizhangu (Asparagus racemosus,Wild) 
4. Mullilavu ver (Bombax malabaricum,Dc) 
5. Nelli ver (Phyllanthus emblica,Linn) 
6. Seenthil sarkarai (Tinospora cordifolia,Wild)  and 
7. Karkandu podi (Quantity equal to the powder of all the above) 
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METHOD OF PURIFICATION :  
          (Ref :Sigicha Rathina Deepam, Author :C.Kannusamipillai. Edition 2007) 
POONAIKALI VITHAI CHOORANAM ( Internal) 
1. Poonaikali vithai( Mucuna pruiens, Linn Dc) 
a. Part used :Seed 
b. Fry the seeds in a mud vessel . 
2. Siru nerunjil vithai (Tribulus terrestris, Linn ) 
a. Part used :Seed 
b. Dry the seed in shade and powder it. 
3. Thaneer vittan (Asparagus racemosus,Wild.) 
a. Part used: Root tuber 
b. Wash the root tuber with running water and dry it. 
4. Mullilavu ver (Bombax malabaricum,Dc.) 
a. Part used :Root 
b. Dry the root in shade and powder it. 
5. Nelli ver (Phyllanthus emblica,Linn.) 
a. Part used : Root 
b. Dry the root in shade and powder it. 
6. Seenthil sarkarai (Tinospora cordifolia,Wild.)   
a. Part used : Stem 
b. Mix well in water, filter it and dry in sunlight. 
PREPARATION:  All the ingredients were taken in the right proportion in a pestel mortar, 
ground and filtered as fine powder. 
DRUG STORAGE : The trial drug ―POONAIKALI VITHAI CHOORANAM ‖ ( internal) was 
stored  in a clean and dry wide mouthed glass bottles. 
DISPENSING:   
The chooranam was dispensed in sachet  
Quantity of Medicine A packet of 24 sachets for 12 days each sachets consist of 6 gm. 
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MUCUNA  PRURIENS 
Family : Fabaceae 
 
Plant description: Twining herbs, branches terete, striate, downy pubescent. 
Leaves trifoliate, leaves ovate-rhomboid,apprised white-pubescent. Flowers 
dark purple with yellow shade on the petal in long axillary racemes. Pods 
curved, prominently s- shape,densely silk pubescent with persistent pale 
brown or gray irritant bristles,seeds 4-6, orbicular. 
 
Geographical distribution :   
World :Cultivated in Tropics 
India : occasionally in damp places, bushes, hedges and ravines throughout India. 
  
Vernacular names: Sanskrit: Atma gupta, hindi: kivach,  kan : Turachi- gida,  telgu: 
Dulagondi, Tamil  :  Poonai kali. 
Trade name : Common cowitch 
                â¨Éì¸¡Ä¢ 
¾Ø¾¡¨Ç¿¡ü Èò§¾¡Î º¡¡¢Ãò¾ô §À¡ìÌõ 
ÀØÐÒ¡¢ ¸¢ýÈ¸Ãô À¡Ûõ - «Ø§¾Ìó 
¾¡ÄÁ¢¨º Å¢óÐ×Á¡ï º¡üÈü ¸Õõâ¨Éì 
¸¡Ä¢ Å¢¨¾¨Âì ¸ÆÚ. 
     - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 Taste - Astringent. 
 Potency - Moderate. 
 Division - Sweet. 
 Part used- Seed. 
 Action- Nervine tonic, Aphordisiac 
Medicinal uses:  
 Traditionally in India the seeds of   Mucuna  pruriens are used as a 
tonic and aphrodisiac for male virility. 
 Seeds are highly reputed medicine for curing Parkinson’s disease. 
 It is used in fracture healing. 
 It is used as anti depressant drug. 
 The pods are anthelmintic 
 The seeds are anti- inflammatory 
 The hairs are used as vermifuge 
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Tribulus terrestris : 
Syn: Tribulus lanuginosus L 
        Tribulus maximus var.roseus kuntze 
Family:Zygophyllaceae 
Plant description: The nutlets are hard and bear to four sharp spines, 10mm(0.39) 
long and 4-6mm(0.16-0.24) broad point to point. These nutlets strikingly resembles 
goats’ or bulls’ heads.  
Geographical distribution: 
World: Native to Southern Asia. 
India: Forests throughout India. 
Names: goat's-head,bindii,
 
bullhead,  burra gokharu, bhakhdi, caltrop,small 
caltrops,cat's-head,devil's  eyelashes, devil's-thorn, devil's-weed,puncture vine, 
puncturevine, and tackweed. 
Trade name : Gokhru 
                º¢Ú¦¿Õïº¢ø 
 
¦ºôÒ¦¿ Õïº¢ø ¾¢Ã¢§¾¡¼õ ¦À¡ì¸¢Îõ 
¦ÅôÒ Ó¾Ä¨ÉòÐõ Å£ðÎí¸¡ñ-¦ºôÀÃ¢Â 
Íì¸¢Ä§Á ¸õ§À¡÷ìÌó ¦¾¡ø¨ÄÂÉø Á¡üÚõ 
Á¢ìÌ ÁÕóÐ¿£ Å£û. 
-«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Taste- Astringent,sweet  potency - Moderate, class - sweet. 
Action: Aphrodisiac 
Medicinal uses: 
 Tribulus seems to work by increasing the level of luteinzing hormones.this 
hormones sends a signal through the body to start producing testosterone. 
 The popularity of tribulus as an herbal remedy for erectile dysfunction. 
Research papers: The diuretic properties of TT are due to large quantities of nitrates and 
essential oil present in its fruits and seeds. (Divya kanchan 2003) plant Med.53:8- 2003. 
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Asparagus  racemosus  Willd. 
Family: Liliaceace 
 
 Plant description:  perennial armed climbing shrub. Roots tuberous. Stem 
angular. Leaves scaly.cladodes 2-6 in whorl, linear, falcate. Flowers white in 
racemes. Fruit berry, globose, red when ripe  3-6 seeded. 
Geographical distribution: 
World: south Asia, China, Malaysia, and Australia. 
India : occasional in forests all over India. 
 
Names: sana: satavari Guj:Ekalakanto,Shatavari; Hind : Chatwal, kan: 
Aheruballi,mal: Shatavalli,Mar:Zatar,  Tamil: Kilvari,Catavari; 
tel:Pilligadallu. 
 
Trade name : Wild Asparagus. 
                     
                         ¾ñ½£÷Å¢ð¼¡ý 
¿£¡¢Æ¢¨Åô §À¡ìÌõ ¦¿Î¿¡ðÍ Ãò¨¾¦ÂÄ¡õ 
°¨ÃÅ¢Îò §¾¡¼× ¨ÃìÌí¸¡ñ-¿¡¡¢Â¡§Ã! ¬ 
¦Åñ½£÷¦Àö§º¡Á§¿¡ö¦Åð¨¼Â½ø¾½¢ìÌó
¾ñ½£÷Å¢ð ¼¡ý¸¢ÆíÌì ¾¡ý. 
                  -«¸ò¾¢Â÷Ì½Å¡¸¼õ 
 
 Taste -Sweet. 
 Potency - Moderate. 
 Division - Sweet. 
 Part used- leaves. 
 
Action- Aphrodisiac, Nutritive,Antispasmodic. 
Medicinal uses:  
 The root is used in indigenous medicine. 
 It is considered aphrodisiac and demulcent. 
 It is prescribed for increasing the secretion of milk 
 The root is used to cure tuberculosis, leprosy, skin diseases, 
inflammations 
 
RESEARCH PAPERS: 1. Methanolic extract of fresh roots showed 
gastroduodenal ulcer protective activity ( Sairam et al., 2003) 
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Bombax Malabaricum: 
Syn: Bambax ceiba.f. 
        Bambax heptaphyllum Cav. 
Family: Bombacaceae 
Plant description: Bombax species are among the largest tree in their 
regions,reaching 30 to 40 meteres in height and up to 3 meteres trunk diameter. 
Geographical distribution: 
World: Native to western Africa. 
India: Forests throughout India. 
Names:  Silk cotton tree, simal, red cotton tree, kapok, and simply bombax. In 
Chinese they are known as Mumian. 
Trade name :  kapok tree. 
             ÓûþÄ× 
 
¾óÐ§Á ¸ïº¢Ú¿£÷ò ¾¡¨Ã¦Åô ÀõÅ¡Ô 
×ó¾ÅÕ §À¾¢Â¢¨Å §Â¡ðÎí¸¡ñ- Óó¾¢ì 
¸¢Ç÷Åû¨Ç À¡ÔõÅÃ¢ì ¦¸ñ¨¼ Å¢Æ¢Â¡ö 
ÅÇ÷Óû Ç¢Ä× ÁÃõ. 
                                                             - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Taste- Astringent,sweet  potency - Moderate, class -sweet. 
Action: Aphrodisiac 
Medicinal uses: 
 The roots are valuable as an aphrodisiac and to prevent premature ejaculation. 
 The mashed roots with nutmeg powder are an effective adjuvant in diabetes. 
 
 Research papers: The extract of stem bark of Bombax ceiba has significant anti-
obesity potential against HFD induced experimental obesity, possibly due to 
modulation of FAS and PTP-1B signaling in Wistar rats due to the presence of active 
flavanoids and lupeol respectively. Verma Rameshwar*, Devre Kishor, 
GangradeTushar ,Gore Siddharth, Gour Sudarshan G.R.Y. Institute of Pharmacy, 
Vidhya vihar, Borawan (Khargone), M.P.-451228, India. 
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Phyllanthus emblica: 
Syn: Emblica arborea Raf. 
        Emblica officinalis Gaertn. 
Family: Phyllanthaceae  
Plant description: The tree is small to medium in size, reaching 1–8 m (3 ft 3 in–26 ft 3 in) in 
height. The branchlets are not glabrous or finely pubescent, 10–20 cm (3.9–7.9 in) long.The fruit 
is nearly spherical, light greenish yellow, quite smooth and hard on appearance, with six vertical 
stripes or furrows.  
Geographical distribution: 
World: Large area ranging from Nepal and Sri Lanka . 
India: Forests throughout India. 
Names:  Phyllanthus emblica, also known as emblic, emblic myrobalan, myrobalan, Indian 
gooseberry, Malacca tree, or amla from Sanskrit amalika 
Trade name : Amla/ Emblica Officinalis/ Indian Gooseberry 
               ¦¿øÄ¢ 
ÅÁÉõ «§Ã¡º¢ÂÚõ Å¡¾Ó¾ý ãýÚï 
ºÁÉ ÓÚÁÄÓï º¡Úõ-«Á¡ÉÍÃõ 
ÒøÄ¢ÅÕ §¾¡¼ºýÉ¢ ¦À¡øÄ¡î ¦ºÂÖõ §À¡õ 
¦¿øÄ¢ÁÃ §Å¨Ã ¿¢¨É. 
                                                           - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Taste- Sour,Astringent,Sweet  potency - Moderate, class – sweet. 
Action: Aphrodisiac 
Medicinal uses: 
 As an extremely rich source of vitamin C, Indian gooseberry is one of the best 
remedy for scurvy. 
 It also balance both pitha and vaatha by virtue of its sweet taste. The kapha is 
balanced primarily due to its drying action. 
Research papers: There is Preliminary evidence in vitro that extract of P.emblica 
induce apoptosis and modify gene expression in osteoclasts.(Penolazzi.l,Lampronti I, 
Borgatti.M (2008). 
 
47 
 
 
Tinospora cordifolia: 
Syn: Tinospora baenzigeri Foramen 
        Tinospora capillipes Gagnep. 
Family:Menispermaceae 
Plant description: It is a large, deciduous extensively spreading climbing shrub with 
several elongated twining branches. Leaves simple, alternate, exstipulate, long 
petioles up to 15 cm long, roundish, pulvinate, both at the base and apex with the 
basal one longer and twisted partially and half way around.  
Geographical distribution: 
World: Native to tropical area of Myanmar,and Sri Lanka. 
India: Throughout tropical region of India. 
Names:  Heart leaved, Moon seed , guduchi, giloy  
Trade name : Giloy 
             º£ó¾¢ø 
§Á¸¦ÁÛ Á¡¾Àò¾¡ø ¦Åó¾ ×Â¢÷ôÀÂ¢¨Ãò 
¾¡¸ Á¼í¸ò ¾½¢ò¾Ä¡ø-¬¸õ 
«ÁÃ ¦ÃÉÄ¢Õì¸ Å¡¾Ã¢ò¾ Ä¡§Ä 
«Ó¾ÅøÄ¢ ºïº£Å¢ Â¡õ. 
                          - «¸ò¾¢Â÷ Ì½Å¡¸¼õ  
Taste-Bitter, potency - Hot division, class - pungent. 
Action: Aphrodisiac 
Medicinal uses:   
 The juice or powder of Giloy Stem is useful in treating various type of cancer. 
Giloy is an immunomodulatory. 
 Tinospora cordifolia is a top herbal remedy in preventing Swine Flu. 
Research papers: The alcoholic extract of T. cordifolia has been found to exert anti-
inflammatory actions in models of acute and subacute inflammation . The water-soluble 
fraction of 95% ethanolic extract of T. cordifolia plant has shown significant antipyretic 
activity.(Avinish k, Upadhyay,Kaushal kumar) internal j Ayurveda Res .Apr-june 2010 
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Saccharum Officinarum: 
Syn: Arundo saccharifera Garsault 
        Saccharum hybridum R.M.Grey 
Family: poaceae ( gramineae) 
Plant description: S. officinarum,a perennial plant, grows in clumps consisting of a 
number of strong   unbranched stems. The stems vary in colour, being green, 
pinkish, or purple and can reach 5 m (16 ft) in height. They are jointed, nodes 
being present at the bases of the alternate leaves. 
Geographical distribution: 
World: It is originated in south Asia 
India: First domesticated in India. 
Names:  Sugar cane, Noble cane, whilt salt 
Trade name : Sugarcane. 
            ¸ü¸ñÎ 
 
®È¢ý ¾ÊôÒ Á¢ÕÁÖõÀø Å¡ó¾¢¸Ùï 
º£Ú¸À ÓðÊÉÓï §ºÃ¡§¾-§¾È¢Â¿ü 
¦º¡ü¸ñ ÊÇíÌÂ¢ø¸û ÝÆ Á¼ÅÉ§Á 
¸ü¸ñ ¦¼É×¨ÃìÌí ¸¡ø. 
«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Taste- Sweet, potency - moderate, class - sweet. 
Action: Anti septic, Demulcent 
Medicinal uses: 
 The juiciest and sweetest sugarcane is the tropical green sugar cane.it 
strengthens stomach,kidney,heart,eyes,brain and sex organs. 
 The sugarcane can be used as simple energizer and protein supplement in 
infectious fevers. 
Research papers: The phenolic extract obtained from sugar cane juice showed a 
protective effect against in vivo MeHgCl intoxication (Antioxidant activity).(Sepideh 
Miraj) Der Pharmacia Lettre,2016,8(13):223-225) 
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BACK GROUND: 
   In 20th century usage of herbal based medicinal therapy gained importance 
and  found their place  in 40% of prescription  because of  their lesser side effects on par with 
other chemical drugs. The usage of medicinal plant products in the form of plant extracts and 
their active components etc. 
    Yugi muni had done a lot of contribution to the siddha system, includes the 
classification of disease into 4448. AAN MALADU  is one among them. According to Yugi 
muni in Aan maladu the semen exhibits the following characters such as absence of  
sweetness, buoyancy on water.He further explained the character of urine in Aan maldu as 
froth in urine and symptoms like absence of virility. 
   Sukkilam one among the seven udal thathukkal is affected in Aan maladu. 
Aan maladu is known as male Infertility in modern science . Most cases of male infertility are 
due to an abnormal sperm,abnormal sperm count and low sperm motility.  Infertility is the 
inability of a sexually active, non contraception couple to achieve pregnancy in one year. As 
per WHO guidelines a report with count less than 15 million / ml is oligospermia.  There was 
a time when infertility was only limited to women. In present scenario male infertility is 
blamed in 50 % of cases where couples could not conceive naturally.  Male infertility is a 
global problem in the field of reproductive health. . Infertility bears a social stigma.The 
incidence of infertility is follows males - 40% females- 40% and both sex -20%.  Most of the 
cases are hailing from IT back ground, chemical industry, oil refineraries, other than 
occupation viral infection during childhood (ex mumps) endocrine disorder, trauma(testes),  
,low economic standards, can also lead to rise in infertility rate.  
   The research study entitled Aan maldu ( Male infertility) mainly focus on 
outcome of qualitative and quantitative  analysis of semen in oligospermia patients with the 
trial drug poonaikali vithai  chooranam . Poonaikali vithai chooranam is a poly herbal 
compound .The ingredients of poonaikali vithai  chooranam are  possessing anti oxidants ( 
kayakalpha drugs ) and aphrodisiac properties. 
                        Poonaikali vithai(Mucuna pruriens), Siru nerunjil vithai (Tribulus terrestris), 
Thanneer vittan kizhangu (Asparagus racemosus), Mullilavu ver (Bombax malabaricum), 
Nelli ver (Phyllanthus emblica), Seenthil sarkarai (Tinospora cordifolia)  and, Karkandu podi  
are included in the trial drug. 
    Since the trial medicines is yet to be documented for its efficacy, it is 
essential to do safety studies before going for clinical trial. 
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OBJECTIVE :  
Primary objective :   
  To evaluate the therapeutic efficacy of siddha formulation  ―Poonaikali vithai 
chooranam‖  in the treatment of  AAN MALADU ( male infertility) 
Secondary objective:   
  To evaluate the safety profile ( Acute, Sub acute  toxicity studies) of the trial 
drug.To study the siddha cofactors  such as age, occupations, socio economic status, dietary 
influence.etc 
STUDY DESIGN & CONDUCT OF STUDY: 
Study type : An open clinical trial 
Study place  : OPD Of Ayothidass pandithar hospital,National Institute of Siddha ,    
  Tambaram sanatorium, Chennai-47. 
Study period  : 12 months 
Sample size  : 40 patients  
TREATMENT: 
MEDICINE  NAME : 
               “Poonaikali vithai chooranam”     
 Ref  : GUNAPADAM MOOLIGAI VAGUPU 
 Author : Vaithiya rathinam K.S Murugesa muthalaiyar: 1
st
 Edison  pg no 708  
  (publication year 1936) 
DOSAGE  :  6 gm twice a day After food  
ADJUVANT : Cow’s Ghee 
DURATION :  48 days  
ROUTE  OF DRUG ADMINISTRATION : oral route                       
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 STANDARD OPERATING PROCEDURE OF THE TRIAL DRUG -“POONAIKALI 
VITHAI CHOORANAM”   
SOURCE OF RAW DRUGS:  
           The required raw drugs for the preparation of    Poonaikali vithai chooranam  will be  
purchased from a well reputed country shop. The raw drugs will be authenticated by the Asst. 
Prof of medicinal botany at NIS. Then the raw drugs will be purified as mentioned in siddha 
literature. The medicine is prepared in Gunapadam lab of National Institute of Siddha. 
REQUIRED RAW DRUGS: 
      1. poonaikali vithai(Mucuna pruriens, Linn Dc) 
2.Siru nerunjil vithai (Tribulus terrestris,Linn) 
3.Thanneer vittan kizhangu (Asparagus racemosus,Wild) 
4.Mullilavu ver (Bombax malabaricum,Dc) 
5.Nelli ver (Phyllanthus emblica,Linn) 
6.Seenthil sarkarai (Tinospora cordifolia,Wild)  and 
7.Karkandu podi (Quantity equal to the powder of all the above) 
METHOD OF PURIFICATION :  
- (Ref :Sigicha Rathina Deepam, Author :C.Kannusamipillai. Edition 2007) 
POONAIKALI VITHAI CHOORANAM ( Internal) 
1.POONAI KALI( Mucuna pruiens, Linn Dc) 
a.Part used :Seed 
                    b.Fry the seeds in a mud vessel . 
2.Siru nerunjil vithai (Tribulus terrestris, Linn ) 
a.Part used :Seed 
b.Dry the seed in shade and powder it. 
3.THANEER VITTAN (Asparagus racemosus,Wild.) 
                    a. Part used: Root tuber 
b. Wash the root tuber with running water and dry it. 
4.Mullilavu ver (Bombax malabaricum,Dc.) 
                    a. Part used :Root 
                    b.Dry the root in shade and powder it. 
5.Nelli ver (Phyllanthus emblica,Linn.) 
                     a.Part used : Root 
                     b.Dry the root in shade and powder it. 
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6.Seenthil sarkarai (Tinospora cordifolia,Wild.)   
                   a.Part used : Stem 
b.Mix well in water, filter it and dry in sunlight. 
PREPARATION: 
  All the ingredients will be taken in the right proportion in a pestel mortar, 
grinded and filtered as fine powder. 
DRUG STORAGE :  
  The trial drug ―POONAIKALI VITHAI CHOORANAM ‖ ( internal) is 
stored in clean and dry wide mouthed glass bottles. 
DISPENSING:   
 The chooranam will be dispensed in sachet 
Quantity of Medicine  
 A packet of 24 sachets for 12 days each sachets consist of 6 gm. 
SUBJECT SELECTION: 
                As and when patients reporting at OPD of Ayothidass Pandithar Hospital with 
symptoms mentioned in inclusion criteria will be subjected  to screening  test & 
documentation will be done by using screening proforma. 
INCLUSION CRITERIA: 
1. Male infertile 
2. Age  21- 45 year 
3. Maritial status -  more than 1 year 
4. Sperm count   ≤  40 million / ejaculation  
5. Motility less than  ≤  50 % 
6. Patient who is willing to sign the informed consent stating that he 
will continuously stick to the treatment during 48days but can opt out 
of the trial of his own conscious discretion. 
7. Patients who are willing   to give specimen of blood , urine and 
semen before and after treatment.  
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EXCLUSION CRITERIA 
1. Azoospermia 
2. Hydrocele 
3. Diabetes mellitus 
4. Hypertension 
5. Endocrine disorders 
6. Caridiac diseases 
7. VDRL & STD 
8. Inguinal Hernia 
9. Renal diseases 
10. Varicose veins 
WITHDRAWAL CRITERIA 
1. Intolerance to the drug & development of adverse reactions during 
drug trial. 
2. Poor patient compliance & defaulters. 
3. Patient turned unwilling to continue in the course of clinical trial. 
4. Increase in severity of symptoms. 
TEST & ASSESSMENTS 
A. CLINICAL ASSESSMENT 
       SIDDHA ASSESSMENT 
B. ROUTINE INVESTIGATION 
C. SPECIFIC INVESTIGATION 
A. CLINICAL ASSESSMENT (5) 
1. Premature ejaculation  
2. Nocturnal emission 
3. Erectile dysfunction 
4. Painful coitus 
5. Painful micturition  
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SIDDHA ASSESSMENT 
1.Thinai : 
• Kurinchi (hill areas) 
• Mullai ( forest ) 
• Marutham ( fertile land ) 
• Neidhal ( coastal area ) 
• Palai ( desert ) 
2. Paruva Kalam (season )  
• Karkaalam (Aug 18 – Oct 17) 
• Koothir kaalm (Oct 18 – Dec 16) 
• Munpanikaalm (Dec 17 – Feb 12) 
• Pinpani kaalam (Feb 13 – April 13) 
• Ilavenil kaalam (April 14 – June 14) 
• Muthuvenil kaalam (June 15 – Aug 17) 
3. Poripulankal: 
• Mei (Skin etc) 
• Vaai (Tongue etc) 
• Kan (Eye etc) 
• Mooku (Nose etc) 
• Sevi (Ear etc) 
6.Ennvagaithervu ( Eight types of Examination): 
• Naadi 
• Sparisam 
• Naa 
• Niram 
• Mozhi 
• Vizhi 
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• Malam 
• Moothiram 
 - Neerkuri 
 - Neikuri 
B .  ROUTINE INVESTIGATION 
• Hb(gm/dl) 
• Total WBC Count(cells/cumm) 
• DC-  Polymorphs(%) 
• Lymphocytes(%)  
• Eosinophils (%) 
• Monocytes (%) 
• Basophils(%)  
• Total RBC count million cells/cumm) 
• ESR(Men 6-12mm/hr  Women 7-18 mm/hr) 
•  B.glucose (mg/dl)  F & PP 
LIPID PROFILE 
• Serum T.cholesterol(mg/dl)- 
•  HDL cholesterol(mg/dl)- 
•  LDL cholesterol(mg/dl)- 
• VLDL cholesterol(mg/dl)- 
• Serum triglycerides  (mg/dl)-    
 KIDNEY FUNCTION TEST 
•  B.urea(mg/dl)  
• S. total creatinine (mg/dl) 
LIVER FUNCTION TEST 
• S.total bilirubin(mg/dl)  
• S.direct bilirubin (mg/dl) 
• S. indirect bilirubin (mg/dl) 
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• SGOT(u/l) 
• SGPT (u/l) 
• S.alkaline phosphataseu/l)  
• S.total protein(g/dl)  
• S. albumin (g/dl) 
• S.globulin (g/dl) 
• S. calcium (mg/dl) 
• S. phosphorous (mg/dl) 
URINE EXAMINATION  
•  Albumin 
• Sugar (Fasting & post prandial) 
• Deposits  
• Bile salts  
• Bile pigments 
• Urobilinogen  
SPUTUM  - AFB 
SPECIFIC INVESTIGATION 
        Semen analysis –   
  Volume 
  Colour  
  Appearance 
  Viscosity 
  Liquification time 
  Fructose 
  Sperm count 
  Motility 
             Morphology 
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       STUDY ENROLLMENT: 
 In this clinical trial patients reporting at NIS OPD with the clinical symptoms of  
premature ejaculation, Nocturnal emission, Erectile dysfunction, Painful coitus, 
Painful micturition will  be examined clinically for enrolling in the study based on the 
inclusion and exclusion criteria.  
 The patients in this study will be  informed (Form-V ) about the objective of the  
study, trial drug, possible outcomes in their own language and terms understandable 
to them. 
 After ascertaining the patient’s  willingness, informed consent would be obtained in 
writing from them in the consent form .(Form- VI) 
 All these patients will be given unique registration card in which patient’s registration 
number of the study, Address, Phone number and Doctors phone number etc. so as to 
report  easily and if any adverse reactions arise. 
 Complete clinical history, complaints and duration, examination findings-- all will be 
recorded in the prescribed Proforma in the history and clinical assessment forms 
separately. Screening Form- I will be filled up; Form –II and Form –III will be used 
for recording the patient’s history, clinical   examination of symptoms and  signs and 
laboratory investigations respectively. 
 Patients would be advised to take the trial drug and appropriate dietary advice (Form 
IV-D) would be given according to the patients’ perfect understanding. 
CONDUCT OF THE STUDY: 
          The trial drug  POONAIKALI VITHAI CHOORANAM (Internal)  is given for 48 
days.        
          Patients are advised to visit the hospital once in 12  days to get the trial drug.  At each 
clinical visit clinical assessment will be  done and prognosis will be noted.  
          Laboratory investigations &  SEMEN ANALYSIS will be  done  on 0th day   & 48 th 
day of the trial  for OP patients .  
If any trial patient who fails to collect the trial drug on the prescribed day but wants to 
continue in the trial from the next day or two, he will be allowed, but defaulters of one week 
and more will not be allowed to continue and be withdrawn from the study with fresh case 
being included.         
 
 
64 
 
DATA MANAGEMENT 
• After enrolling the patient in the study, a separate file for each patient will be opened 
and all forms will be filed in the file. Study No. and Patient No. will be entered on the top of 
file for easy identification. Whenever the study patient visits OPD during the study period, the 
respective patient file will be taken and necessary recordings will be made at the assessment 
form or other suitable forms. 
• The screening forms will be filed separately. 
• The Data recordings will be monitored for completion by HOD and adverse event by  
Sr.Research Officer (Statistics). All forms will be further scrutinized in presence of 
Investigators by Sr.Research Officer (Statistics) for logical errors and incompleteness of data 
to avoid any bias. No modification in the results is permitted for unbiased reports. 
 STATISTICAL ANALYSIS: 
          All collected data will be entered into the computer and manually cross-checked the 
correctness of the data entry. The clinical symptoms and labarotary investigation of semen  
will be analyzed by comparing the two point of data (before and after treatment) paired test 
and chi-square test will be employed to study the efficacy of treatment. Further, the effect of 
co factors ( age, occupation, socio economic status.etc) will also be statistically analyzed.  
OUTCOME 
1. PRIMARY OUT COME 
 Primary Outcome is mainly assessed by increase in the  sperm count and motility % 
RESULT 
SPERM COUNT & MOTILITY 
(/ ejaculates) 
FROM TO 
GOOD 
SPERM COUNT * ≤ 40    million ≥  60    million 
MOTILITY %  #( RM+PM) ≤ 50% ≥   70 % 
MODERATE 
SPERM COUNT * ≤ 40    million >  50   million 
MOTILITY %  #( RM+PM) ≤ 50% ≥  60 % 
MILD 
SPERM COUNT * ≤ 40    million 40-50  million 
MOTILITY %  #( RM+PM) ≤ 50% >  50 % 
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NOTE: 
  *   As per 1999 WHO criteria (1) standard value for total number of spermatozoa ≥ 
40 million per ejaculates. 
 #   As per 1999 WHO criteria (1) standard value for motility is  ≥ 50 %  million per 
ejaculates. 
  Progressive motility (PM) -  ≥  50 % 
  Rapid motility (RM)  -  25 % 
2. SECONDARY  OUT COME 
 Secondary  Out Come is mainly assessed by reduce the clinical symptoms. 
 ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT: 
  If the trial patient develops any adverse reaction. It will be recorded  in 
pharmacovigilence form, and he would be immediately referred to of Pharmacovigilance 
department of NIS  and proper management will be given  in OPD of National institute of 
siddha.  
ETHICAL ISSUES 
1. Informed consent will be obtained from the patient after explaining about the clinical 
trial  in the understandable language to the patient. 
2. The data collected from the patient will be kept confidentially. 
3. After getting the consent of the patient in the consent form they will be enrolled in the 
study 
4. Treatment would be provided free of cost.  
5. No other external or internal medicines will be used. There will be no infringement 
on the rights of patient.    
6. To prevent any infection, while collecting blood sample from the patient, only  
disposable      syringes, disposable gloves, and needles  will be used under proper 
sterilization cover. 
7. The patients who are excluded ( as per exclusion citeria ) are given proper treatment 
at National Institute of Siddha 
8. In conditions of treatment failure, adverse reactions, patients will be given alternative 
treatment at the National Institute of Siddha with full care throughout  the end of the 
treatment
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ASSESSMENT FORM 
FORM I  SCREENING AND  SELECTION PROFORMA 
FORM II  CLINICAL RESEARCH FORM 
FORM lll  LABORATORY INVESTIGATION ON ENROLLMENT AND  
    CONCLUSION OF TRIAL 
FORM IV  DRUG COMPLIANCE FORM  
FORM V  PATIENT INFORMATION SHEET  
FORM VI      PATIENT CONSENT FORM 
FORM VII WITHDRAWAL FORM / ADVERSE REACTION FORM /     
PHARMACOVIGILENCE FORM 
FORM VIII    DIETARY ADVICE FORM 
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ACUTE ORAL TOXICITY STUDY OF POONAIKALI VITHAI 
CHOORANAM 
                                (OECD GUIDELINE – 423)     
 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals of a single 
sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on average 2-4 
steps may be necessary to allow judgement on the acute toxicity of the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank substances in a 
similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification purposes and 
hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise LD50, but 
does allow for the determination of defined exposure ranges where lethality is expected 
since death of a proportion of the animals is still the major endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least two doses 
result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states improves 
the opportunity for laboratory to laboratory reporting consistency and repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of a minimum 
number of animals per step, sufficient information is obtained on the acute toxicity of the test 
substance to enable its classification. The substance is administered orally to a group of 
experimental animals at one of the defined doses. The substance is tested using a stepwise 
procedure, each step using three animals of a single sex. Absence or presence of compound-
related mortality of the animals dosed at one step will determine the next step, i.e. 
− no further testing is needed 
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− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose level. The method 
will enable a judgment with respect to classifying the test substance to one of a series of toxicity 
classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent species may be 
used. Healthy young adult animals are commonly used laboratory strains should be employed. 
Females should be nulliparous and non-pregnant. Each animal, at the commencement of its 
dosing, should be between 6 to 8 weeks old and the weight (150-200gm) should fall in an 
interval within±20 % of the mean weight of any previously dosed animals.  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  Although the 
relative humidity should be at least 30% and preferably not exceed 70% other than during room 
cleaning the aim should be 50-60%. Lighting should be artificial, the sequence being 12 hours 
light, 12 hours dark. For feeding, conventional laboratory diets may be used with an unlimited 
supply of drinking water. Animals may be group-caged by dose, but the number of animals per 
cage must not interfere with clear observations of each animal. 
Preparation of animals:  The animals are randomly selected, marked to permit individual 
identification, and kept in their cages for at least 7 days prior to dosing to allow for 
acclimatization to the laboratory conditions 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS,Madhavaram, Chennai. All the animals were kept under standard environmental 
condition (22±3°C).  The animals had free access to water and standard pellet diet (Sai meera 
foods, Bangalore). 
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Preparation of animals:   
  The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for 
acclimatization to the laboratory conditions 
 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to administration of the, 
Poonaikali vithai choornam.  
The principles of laboratory animal care were followed and the Institutional Animal Ethical 
Committee approved the use of the animals and the study design 
 
IAEC approved  Number: IAEC/XLIX/13/CLBMCP/2016 
 
Test Substance  : POONAIKALI VITHAI CHOORNAM 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual     
                              marking by using Picric acid.  
Number of animals               : 3 Female/group,  
 Route of administration      :   Oral  
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd, Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages    
                 provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
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Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days  
Administration of Doses:  
 Poonaikali vithai choornam was suspended in water and administered to the groups of 
wistar albino rats in a single oral dose by gavage using a feeding needle. The control group 
received an equal volume of the vehicle. Animals were fasted 12 hours prior to dosing. 
Following the period of fasting, the animals were weighed and then the test substance was 
administered. Three Female animals are used for each group. The dose level of 5, 50, 300 and 
2000 mg/kg body weight was administered stepwise. After the substance has been administered, 
food was withheld for a further 3-4 hours. The principle of laboratory animal care was followed. 
Observations were made and recorded systematically and continuously as per the guideline after 
substance administration. The visual observations included skin changes, mobility, aggressively, 
sensitivity to sound and pain, as well as respiratory movements. Finally, the number of survivors 
was noted after 24 hrs and these animals were then monitered for a further 14 days and 
observations made daily. The toxicological effect was assessed on the basis of mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 minutes, 
periodically during the first 24 hours, with special attention given during the first 4 hours, and 
daily thereafter, for a total of 14 days, except where they need to be removed from the study and 
humanely killed for animal welfare reasons or are found dead. It should be determined by the 
toxic reactions, time of onset and length of recovery period, and may thus be extended when 
considered necessary. The times at which signs of toxicity appear and disappear are important, 
especially if there is a tendency for toxic signs to be delayed. All observations are systematically 
recorded with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, and also respiratory, 
circulatory, autonomic and central nervous systems, and somatomotor activity and behavior 
pattern. Attention was directed to observations of tremors, convulsions, salivation, diarrhoea, 
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lethargy, sleep and coma. The principles and criteria summarized in the Humane Endpoints 
Guidance Document taken into consideration. Animals found in a moribund condition and 
animals showing severe pain or enduring signs of severe distress was humanly killed. When 
animals are killed for human reasons or found dead, the time of death was recorded. 
 
Acute oral toxicity study of  Poonaikali vithai choornam 
Table 1: Dose finding experiment and its behavioral Signs of acute oral Toxicity 
Observation done: 
SL              Group 
              CONTROL 
Observation SL Group 
TEST 
GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 
2 Assessments of 
posture 
Normal 2 Assessments 
of posture 
Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of 
Convulsion 
Limb 
paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant 
color change 
7 Change in skin 
color 
No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
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11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle 
gripness 
Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours which  includes 
abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, convolusion, excitation, 
head twitches, lacrimation, loss of corneal reflex, loss of traction, piloerection  reactivity of 
touch, salivation, scratching, sedation, chewing,  head movements, sniffing, straub, tremor and 
writhes, diarrhea, leathery, sleep and coma.  
Body Weight:  
Individual weight of animals was determined before the test substance was administered and 
weights will be recorded at day 1, 7, and 14 of the study. Weight changes were calculated and 
recorded. At the end of the test, surviving animals were weighed and humanly killed. 
 
Food and water Consumption:                                                                                                                  
             Food and water consumed per animal was calculated for control and the treated dose 
groups.  
Mortality: 
           Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test group the 
number of animals used, the number of animals displaying signs of toxicity, the number of 
animals found dead during the test ,description of toxic symptoms,, weight changes, food and 
water intake. 
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No of animals in each group:3 
Table 2 (Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
2000mg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. 
Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. 
Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhea 18. 
Writhing  
19. Respiration 20. Mortality. 
 
(+  Present, -  Absent) 
Table 3 ( Body weight Observation) 
 
 
 
 
 
 
 
 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 210.6±31.474  211.2 ± 14.162 220.2 ± 24.22 
HIGH DOSE 220.5± 27.75 221.4 ± 3.22 224.1 ± 12.72 
P value (p)* NS NS NS 
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Table 3 (Water intake (ml/day) of Wistar albino rats group exposed to                        
Poonaikali vithai choornam): 
 
DOSE 
 
DAYS 
1 6 14 
CONTROL 54 ± 2.22 53±7.42 58.4±2.54 
HIGH DOSE 62.2±1.21 62.8±4.46 64.6±2.22 
P value (p)* NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
Table 4: Food  intake (gm/day) of Wistar albino rats group exposed to  
Poonaikali vithai choornam       
 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 45.24±6.32 45.2±6.32 45.4±4.16 
High DOSE 42.2±1.44 44.8±2.32 46.1±4.14 
 
 
 
 
 
 
 
 
75 
 
                   REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF 
POONAIKALI VITHAI CHOORNAM 
Test Substance  : Poonaikali vithai choornam 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals      : By cage number, animal number   and    individual  
   marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd,         
                  Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages    
                 provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
Table 5  
Groups No of Rats 
Group I  Vehicle control (Water) 12(6male,6 female) 
Group II PVCM- low dose X (20mg) 12 (6male,6 female) 
Group III PVCM- Mid dose  10X (200mg) 12 (6male,6female) 
Group IV PVCM- High dose 20X( 400 mg) 12(6male,6female) 
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 PVCM - POONAIKALI VITHAI CHOORNAM 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. Each group consist 
of 12 animals (Male -6, and Female-6). First group treated as a control and other three group 
were treated with test drug (low, mid, high) for  28 days. Animals were allowed acclimatization 
period of 7 days to laboratory conditions prior to the initiation of treatment. Each animal was 
marked with picric acid. The females were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are low dose 
(X), mid dose dose (10X), high dose (20X). X is calculated by multiplying the therapeutic dose 
(30 ml) and the body surface area of the rat (0.018). i.e X dose is (20MG), 10X dose is 
200mg/animal,20X dose is 400mg/animal. 
 
Preparation and Administration of Dose: 
        Poonaikali vithai choornam suspended in with water, It was administered to animals at the 
dose levels of X, 10X, 20X. The test substance suspensions were freshly prepared every two 
days once for 28 days. The control animals were administered vehicle only. The drug was 
administered orally by using oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of study for the 
following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course of study.  
Food and water Consumption: 
  Food and water consumed per animal was calculated for control and the treated dose 
groups.  
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Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and duration of 
these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of      study. 
Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy of all animals was 
carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted over-night. 
Blood samples were collected from orbital sinus using sodium heparin (200IU/ml) for Bio 
chemistry and potassium EDTA (1.5 mg/ml) for Hematology as anticoagulant. Blood samples 
were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
               Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to histopathological 
investigations. If any abnormality found in the highest dose group than the low, then the mid 
dose group will also be examined. Organs will be collected from all animals and preserved in 
10% buffered neutral formalin for 24 h and washed in running water for 24 h.  The organ sliced 5 
or 6µm sections and were dehydrated in an auto technicon and then cleared in benzene to remove 
absolute alcohol. Embedding was done by passing the cleared samples through three cups 
containing molten paraffin at 50°C and then in a cubical block of paraffin made by the ―L‖ 
moulds. It was followed by microtome and the slides were stained with Haematoxylin-eosin red. 
Statistical analysis:                                                                                                            Findings 
such as body weight changes, water and food consumption, hematology and blood chemistry 
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were subjected to One-way ANOVA followed by dunnet t test using a computer software 
programme – Graph pad  version 7.All data were summarized in tabular form, (Table-6 to 12) 
 
RESULTS 
Repeated Dose 28- day oral toxic study of Poonaikali vithai choornam 
Table 6: Body weight of wistar albino rats group exposed to  Poonaikali vithai choornam       
 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
 
Table 7: Water intake (ml/day) of Wistar albino rats group exposed to Poonaikali vithai choornam 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 55.9 ± 9.72 56±8.22 57.2±2.20 59±2.16 59.4±2.16 
LOW DOSE 58.2±1.21 58.8±3.22 58.9±1.62 60.2±1.28 60.8±1.23 
MID DOSE 62.2±2.12 62.3±1.12 63.1±2.422 63.4±1.14 68.4±1.32 
HIGH DOSE 64.1±1.21 64.2±1.24 64.4±1.14 64.6±1.42 66.8±2.52 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 260.4±12.42  261.4 ± 20.14 261.7 ± 19.60 262.6 ± 19.16 262.4 ± 12.12 
LOW DOSE 240.2 ± 10.12 240.7 ± 38.24 241.4± 42.14 243 ± 52.16 242.42± 12.54 
MID DOSE 196.4± 08.74 196.3 ± 12.14 196.2 ± 88.14 198.1 ± 13.66 199.4 ± 22.10 
HIGH DOSE 207.6± 16.84 207.8 ± 12.42 208.4 ± 22.26 208 ± 24.18 209 ± 56.41 
P value (p)* NS NS NS NS NS 
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Table 8: Food intake (gm/day) of Wistar albino rats group exposed to Poonaikali vithai 
choornam 
       
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 27±5.14 28.5±2.12 29.5±2.17 28.5±1.18 27±2.16 
LOW DOSE 29.7±1.18 29.3±1.41 30.1±1.16 30.4±1.21 31.6±1.42 
MID DOSE 37.2±2.44 37.2±3.60 37.2±4.25 38.2±2.18 38.2±1.44 
HIGH DOSE 29.1±1.14 29.1±1.24 29.6±2.16 29.2±1.20 29.6±3.32 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test 
 
Table 9: Haematological parameters of Wistar albino rats group exposed to Poonaikali 
vithai choornam 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 14.8±0.58 14.80±0.64 15.4±0.66 15.18±0.44 N.S 
Total WBC (×10
3   
l) 
7.91±0.52 7.25±0.16 7.48±0.17 7.20±1.32 N.S 
Neutrophils (%) 30.25±0.04 31.22±0.12 32.10±1.32 33.06±1.20 N.S 
lymphocyte (%) 61.14±1.42 60.12±2.10 60.10±2.22 60.40±2.26 N.S 
Monocyte (%) 1.86±0.07 1.85±0.09 1.66±0.03 1.81±0.06 N.S 
Eosinophil (%) 0.62±0.04 0.65±0.02 0.66±0.01 0.63±0.06 N.S 
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Platelets cells10
3
/µl 786.14±4.42 788.41±4.16 783.13±7.0 787.16±6.74 N.S 
Total RBC 10
6
/ µl 6.88±0.12 6.86±0.46 6.62±0.44 6.15±0.22 N.S 
PCV% 47.56±0.6 47.46±1.13 48±1.28 47.80±2.24 N.S 
MCHC g/dL 34.4±1.32 34.6±1.28 34.28±1.20 34.33±1.12 N.S 
MCV fL(µm
3
) 52.07±3.24 52.20±1.21 53.10±1.34 54.24±1.42 N.S 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
 Table 10 :Biochemical Parameters of of Wistar albino rats group exposed to Poonaikali 
vithai choornam       
 
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
GLUCOSE (R) (mg/dl) 80.24±10.6 80.16±6.14 81.22±14.10 81.62±10.2 N.S 
T.CHOLOSTEROL(mg/dl) 128.16±1.42 129.25±1.22 126.82±1.28 126.22±1.83 N.S 
TRIGLY(mg/dl) 58.36±1.42 58.32±1.28 59.56±1.32 59.66±1.23* N.S 
LDL 81.6±2.53 83.14±2.34 83±2.42     83.44±14.15 NS 
VLDL 16.2±2.34 16.42±4.44 16.44±8.24 16.34±24.26 NS 
HDL 30.16±6.18 30.26±2.25 32.28±4.26 34.48±20.12 NS 
Ratio 1(T.CHO/HDL) 4.12±2.16 4.16±2.14 4.14±2.24 4.26±2.20 NS 
Ratio 2(LDL/HDL) 
 
2.70±1.18 2.74±2.12 2.76±3.10 2.76±18.02 NS 
Albumin (g/dL) 
4.3±0.26 4.63±0.42 4.64±12.42 
4.72±15.68 
NS 
  
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
 
81 
 
 
Table 11: Renal function test of of Wistar albino rats group exposed to Poonaikali vithai 
choornam       
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 23.32±0.99 24.28±0.46 24.16±1.28 24.68±1.22 N.S 
CREATININE(mg/dl) 0.62±0.08 0.61±0.04 0.62±0.06 0.64±0.08 N.S 
BUN(mg/dL) 17.1±0.13 17.10±0.80 17±0.42 17.47±1.12 NS 
URIC ACID(mg/dl) 6.22±0.34 6.11±0.22 6.72±0.24* 6.42±0.26 N.S 
 
  NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
 
 
Table 12: Liver Function Test of of Wistar albino rats group exposed to Poonaikali vithai 
choornam       
 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)*  
T BILIRUBIN(mg/dl). 0.06±0.06 0.05±0.08 0.6±0.06 0.6±0.04 N.S 
SGOT/AST(U/L) 119.15±1.32 119.34±0.52 120.01±1.22 119.75±1.03 N.S 
SGPT/ALT(U/L) 70.13±2.18 70.21±1.44 70.14±1.28 71.12±0.48 N.S 
ALP(U/L) 133.52±4.26 134±12.14 135.12±14.04* 134.23±12.25* N.S 
T.PROTEIN(g/dL) 7.72±0.36 7.78±0.32 7.76±0.24 7.53±0.48 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
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HISTO PATHOLOGY 
CONTROL GROUP 
Kidney           Spleen                                                       Liver  
                 
 
 
 
 
TEST GROUP (HIGH DOSE) 
Kidney    Liver     Spleen 
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 BIO -CHEMICAL ANALYSIS OF  POONAIKALI VITHAI CHOORNAM                                        
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Brown in colour  
2. Solubility: 
a. A little(500mg) of the sample 
is shaken well with distilled water. 
b. A little(500mg) of the sample 
is shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample is taken in a dry test tube and 
heated gently at first and then strong. 
 
 No White fumes   
evolved 
 
Absence of Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the 
sample is made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test:s A filter paper is soaked 
into a mixture of sample and dil. 
cobalt nitrate solution and introduced 
into the Bunsen flame and ignited 
 No Yellow colour 
flame 
Absence of sodium 
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Preparation of Extract:  5gm Of POONAKALI VITHAI CHOORNAM is weighed 
accurately and placed in a 250ml clean beaker and added with 50ml of distilled water. Then it is 
boiled well for about 10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and 
made up to 100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1. 
Test For Sulphate: a.2ml of the above 
prepared extract is taken in a test tube to 
this added 2ml of 4% dil ammonium 
oxalate solution 
Cloudy 
appearance 
present 
Absence of 
Sulphate 
2. 
Test For Chloride: 2ml of the above 
prepared extracts is added with 2ml of dil-
HCl is added until the effervescence 
ceases off.. 
cloudy 
appearance 
present 
Presence 
of Chloride 
3. 
Test For Phosphate: 2ml of the extract is 
treated with 2ml of dil.ammonium 
molybdate solution and 2ml of con.HNo3 
Yellow 
appearance 
present 
Absence 
of Phosphate 
4. 
Test For Carbonate: 2ml of the extract 
is treated with 2mldil. magnesium 
sulphate solution 
Presence 
Cloudy 
appearance 
Presence 
of carbonate 
5. 
Test For Nitrate: 1gm of the substance is 
heated with copper turning and 
concentrated H2So4 and viewed the test 
tube vertically down. 
 
No Brown gas is 
evolved 
 
Absence 
of Nitrate 
6. 
Test For Sulphide: 1gm of the substance 
is treated with 2ml of con. HCL 
No Rotten Egg 
Smelling gas 
evolved 
Presence 
of Sulphide 
7. 
Test For Fluoride & Oxalate: 2ml of 
extract is added with 2ml of dil. Acetic 
acid and 2ml dil.calcium chloride solution 
and heated. 
Presence Cloudy         
appearance 
Presence 
of fluoride and 
oxalate 
8. 
Test For Nitrite: 3drops of the extract is 
placed on a filter paper, on that-2 drops of 
dil.acetic acid and 2 drops of 
No Characteristic 
changes 
Absence 
of Nitrite 
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dil.Benzidine solution is placed. 
9. 
Test For Borate: 
2 Pinches(50mg) of the substance is made 
into paste by using dil.sulphuric acid and 
alcohol (95%) and introduced into the 
blue flame. 
Bluish green 
colour flame not 
appeared 
Absence 
of borate 
 
 II. Test For Basic Radicals   
1. 
Test For Lead: 
2ml of the extract is added with 2ml of 
dil.potassium iodine solution. 
NoYellow 
Precipitate is 
obtained. 
Absence of Lead 
2. 
Test For Copper:One pinch(50mg) of 
substance is made into paste with con. 
HClin a watch glass and introduced into 
the non-. luminuous part of the flame 
No Blue colour 
flame 
No Blue colour 
precipitate 
formed. 
 
Absence 
of copper 
 
 
3. 
Test For Aluminium: To the 2ml of 
extract dil.sodium hydroxide is added in 5 
drops to excess. 
No Yellow colour 
appeared 
Absence 
of aluminium 
4. 
Test For Iron: a.To the 2ml of extract 
add 2ml of dil.ammonium solution 
b. To the 2ml of extract 2ml  thiocyanate 
solution and 2ml  of con HNo3 is added 
 
No red colour 
appear 
 
 
Presence 
of Iron 
 
5. 
Test For Zinc: To 2ml of the extract 
dil.sodium hydroxide solution is added in 
5 drops to excess and dil.ammonium 
chloride is added. 
 
White precipitate 
is   not formed 
Absence 
of Zinc 
6. 
Test For Calcium: 2ml of the extract is 
added with 2ml of 4% dil.ammonium 
oxalate solution 
No Cloudy 
appearance and 
white precipitate 
 
Presence 
of calcium 
7. 
Test For Magnesium: To 2ml of extract 
dil.sodium hydroxide solution is added in 
drops to excess. 
No White 
precipitate is  
obtained 
Presence 
of  Magnesium 
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8. 
Test For Ammonium: To 2ml of extract 
1 ml of Nessler's reagent and excess of 
dil.sodium hydroxide solution are added. 
 
No Brown colour 
appeared 
 
Presence 
of ammonium 
9. 
Test For Potassium: A pinch(25mg) of 
substance is treated of with 2ml of 
dil.sodium nitrite solution and then treated 
with 2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
 
No Yellowish 
precipitate  is 
obtained. 
Presence 
of Potassium 
 
10. 
Test For Sodium: 
2 pinches(50mg) of the substance is made 
into paste by using HCl and introduced 
into the blue flame of Bunsen burner. 
No  yellow 
colour flame 
appeared 
Absence 
of sodium 
11. 
Test For Mercury: 
2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution. 
No yellow 
precipitate is 
obtained 
Absence 
of mercury 
12. 
Test For Arsenic: 
2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution. 
 
No brownish 
red precipitate 
is obtained 
 
Absence 
of arsenic 
 III. Miscellaneous   
1. 
Test For Starch: 
2ml of extract is treated with weak 
dil.iodine solution 
 
blue colour 
developed 
 
presence 
of starch 
2. 
Test For Reducing Sugar: 5ml of 
Benedict's qualitative solution is taken in 
a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes. 
The colour changes are noted. 
 
Brick red 
colour not 
developed 
 
Absence of  reducing 
sugar 
3. 
Test For The Alkaloids: 
a) 2ml of the extract is treated with  2ml 
of dil.potassium lodide solution. 
b)  2ml of the extract is treated with  2ml 
of dil.picric acid. 
c)  2ml of the extract is treated with 2ml 
of dil.phosphotungstic acid. 
No Yellow 
colour 
developed 
Presence 
of Alkaloid 
4. 
Test For Tannic Acid: 
2ml of extract is treated with 2ml of 
dil.ferric chloride solution 
No black 
precipitate is 
obtained 
Absence 
of Tannic acid 
5. 
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution is added. 
Potassium 
permanganate 
is  decolourised 
Absence 
of unsaturated 
compound 
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6. 
Test For Amino Acid: 
2 drops of the extract is placed on a filter 
paper and dried well. 20ml of  Biurette 
reagent is added. 
violet colour 
developed 
Absence 
of amino acids 
7. 
Test For Type Of Compound: 
2ml of the extract is treated with 2 ml of 
dil.ferric chloride solution. 
No green 
colour 
developed 
No red colour 
developedNo 
violet colour 
developed 
No blue colour 
developed 
Absence ooxyquinole 
pinephrine and pyro 
catechol Antipyrine, 
Aliphatic amino 
acidsand meconic 
acid are absent 
Apomorphine 
salicylate and 
Resorcinol areabsent. 
88 
 
 
 
 
 
 
OBSERVATION AND 
RESULTS 
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OBSERVATION AND RESULTS 
Table-1  Age Distribution 
 
Age (yrs) 
Cases 
 
No Percentage (%) 
24 -  29 8 45 
30  -   34 16 18 
35   -   39 12 25 
40 -     45 4 12 
Total 40 100 
 
Chart-1: 
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2) Occupational Status 
Sl. No Nature of Work No. of Cases Percentage 
1 IT Profession 3 7.5% 
2 Jobless 5 12.5% 
3 Electrician 15 37.5% 
4 Businessman-Privately owned 6 15% 
5 Coolie 3 7.5% 
6 Tailor 2 5% 
7 Army 1 2.5% 
8 Building workers 2 5% 
9 Driver 3 7.5% 
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Table-3  Food habits 
Sl. No Dietary Habits No of Cases Percentage 
1 Vegetarian 4 10% 
2 Non Vegetarian 36 90% 
 
Chart-3 
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Table 4  Personal habits 
         
           Personal habits 
 
                                                                                                   
Cases 
 
Smoking/alcohol/tobacco/chewing Numbers Percentage (%) 
Smoking with alcohol 15 37.5% 
Smoking 10 25% 
Tobacco chewers 0 0% 
None of the above habits 15 37.5% 
Total 40 100% 
 
Chart-4: 
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Table-5 Duration of Male Infertility 
Duration (years) 
Cases 
 
Numbers Percentage (%) 
0 – 3 20 50 
4 -6 10 25 
7- 9 8 20 
More than   10 2 5 
Total 40 100 
 
 
Chart-5: 
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Table-6  THINAI 
Thinai 
 
 
cases 
 
No 
Percentage (%) 
 
Kurunji 0 0 
Mullai 2 5 
Marutham 8 20 
Neithal 30 75 
Palai 0 0 
Total 40 100 
 
Chart-6: 
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Table 7  Paruvakalam 
Paruvakalam 
 
Cases 
 
No Percentage( %) 
Karkalam 0 0 
Koothirkalam 0 0 
(Jan-Feb)Munpanikalam 40 100% 
Pinpanikalam 0 0 
Elavenilkalam 0 0 
Muthuvenilkalam 0 0 
Total 40 100 
 
Chart-7: 
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Table 8  Thegi 
 
Type of Theygi 
 
No of cases Percentage 
Vatha thegi 
 
10 25 
Pitha thegi 
 
20 50 
Kaba thegi 
 
10 25 
 
 
Chart-8: 
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Table 9     Three Humors 
 
Type of  Humor No of cases Perceentage 
Vatham 
Abannan affected in 
20 50 
Samanan affected in 22 55 
Pitham 
Sathagam affected in 
40 100 
Kabam 
-Tharpagam affected in 
25 62.5 
 
Chart-9: 
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10  KOSAM (Five sheaths) 
Type of  Kosam No of cases Perceentage 
Annamaya Kosam 40 100 
Pranamaya Kosam 0 0 
Manomaya Kosam 32 80 
Vingnanamaya Kosam 0 0 
Anandhamaya Kosam 40 100 
 
Chart-10: 
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Table 11  Udal Thathukal 
 
Udal Thathukal Cases 
                               No Percentage (%) 
 
Saaram 40            100 
Senneer 40            100 
Oon 0              0 
Kozhuppu 0              0 
Enbu 0              0 
Moolai 0              0 
Sukkilam 40            100 
 
Chart-11: 
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Table 12  Buoyancy on water 
Buoyancy on water 
 
 
No       cases 
 
Percentage (%) 
 
Floating on Water 2 5 
Not floating on Water 38 95 
Total 40 100 
 
Chart-13: 
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14. Neerkuri 
Neerkuri 
Cases 
 
No Percentage 
Pale yellow 12 30 
Yellow 4 10 
Dark yellow 4 10 
Straw 20 50 
Total 40 100 
 
Chart-14: 
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Table 15    Neikuri 
 
Neeikuri 
Cases 
 
Numbers Percentage 
Slowly spread 4 10 
Fastly  spread 30 75 
           No spread 6 15 
Total 40 100 
 
Chart-15: 
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Table 16   History of Masturbation 
Duration (years) 
Cases 
 
No 
 
Percentage (%) 
0 – 5 30                     75 
5 – 10 10 25 
Total 40 100 
 
Chart-16: 
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Table 17 Clinical Features 
Symptoms No of cases 
Before treatment 
Percentage (%) 
After treatment 
Percentage (%) 
Premature ejaculation 30 75 5 
Erectile dysfunction 35 87.5 7.5 
Painful coitus 0 0 0 
Painful Micturition 5 12.5 5 
Nocturnal emission 10 25 5 
Scrotal swelling 0 0 0 
 
Chart-17: 
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Table 18 Semen analysis- Semen Count improvement profile 
Semen Count 
Before treatment presenting 
with 
No of 
cases 
% 
Semen Count 
After treatment improved  
No of 
cases 
% 
 
% 
 
  
Less than 5 Million/ml 10 25 Less than 5 Million/ml 2 5    
More than 5Million -
10Million/ml 
8 20 
More than 5Million -
10Million/ml 
2 5    
More than 11Million-
20Million/ml 
10 25 
More than 11Million-
20Million/ml 
4 10    
More than 21Million-
30Million/ ml 
8 20 
More than 21Million-
30Million/ ml 
8 20    
More than 30 Million/ml 4 10 More than 30 Million/ml 24 60    
 
Chart-18:                        
 
 
 
 
106 
 
 
Table 19 Semen analysis -   Active Motility improvement profile 
 
Active Motility 
Before  treatment 
presenting with 
No of 
cases 
% 
Active Motility 
After treatment improved 
by 
No 
of 
cases 
% 
Less than 5 % 12 30 Less than 5 % 6 15 
More than 5% to 10% 8 20 More than 5% to 10% 10 25 
More than 11% to 20% 10 25 More than 11% to 20% 8 20 
More than 21% to 30% 10 25 More than 21% to 30% 1 2.5 
More than 30 % 0 0 More than 30 % 15 37.5 
 
Chart-19: 
 
 
 
 
 
107 
 
20.  PRIMARY OUT COME 
RESULT SPERM COUNT * 
No 
of 
cases 
% 
 
MOTILITY 
% # 
No of 
cases 
% 
 FROM TO FROM To 
GOOD 
≤ 40    
million 
/ 
ejaculates 
≥  60    
million 
/ 
ejaculates 
20 50.5 ≤ 50% 
≥   70 
% 
 
10 24 
MODERATE 
≤ 40    
million 
/ 
ejaculates 
>  50   
million 
/ 
ejaculates 
6 12.5 ≤ 50% 
≥  60 
% 
 
16 41 
MILD 
≤ 40    
million 
/ 
ejaculates 
50  
million 
/ 
ejaculates 
4 12.5 ≤ 50% 
>  50 
% 
 
4 10 
POOR 
1    
million 
/ 
ejaculates 
≤ 40    
million 
/ 
ejaculates 
10 24.5 ≤ 50% 
≤ 
50% 
10 
25 
 
 
Reference: 
*   As per 1999 WHO criteria (1) standard value for total number of spermatozoa ≥ 40 
million   per ejaculates. 
#   As per 1999 WHO criteria (1) standard value for motility is  ≥ 50 %  million per 
ejaculates. 
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Chart-20: 
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STATISTICAL ANALYSIS 
                All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. STATA software was used to perform 
statistical analysis. Basic descriptive statistics include frequency distributions and 
cross-tabulations were performed. Bar diagram  are used to describe the value of 
different variables for pictorial representation. The quantity variables were expressed 
as mean standard deviation and qualitative data as percentage. A probability value of 
<0.05 was considered to include as statistical significance. Paired t test was performed 
for determining the significance between and after treatment. 
 
Results of statistical analysis of objective parameters (semen analysis) before and 
after treatment of 40 patients of Aan maladu. 
Sno Parameter            Mean Probability value(p) t value 
BT AT 
1 Sperm 
count 
   21.01 60.6 <1.0000   7.49 
2 Sperm 
motility 
23.25 36.75 <1.0000   5.04 
 
Results of statistical analysis of subjective parameters  before and after 
treatment of 40 patients of Aan maladu. 
The mean +  Standard deviation of sperm count before and after treatment 
were 21.01 and 60.6 respectively which is statistically significant (t=7.49  P<1.0000. 
The mean +  Standard deviation of sperm motility before and after treatment 
were 23.25 and 36.75 respectively which is statistically significant (t=5.04  P<1.0000. 
 
 
 
                        
110 
 
 
 
 
 
           LABORATORY        
INVESTIGATIONS 
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SL.NO OP NO Study No 
Hb gm /dl TRBC Million/cumm 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1 I 42978 1 14.8 13.8 4.8          4.1 
2 I 42957 2 16.6 16.4 5.6 5.4 
3 G 95889 3        16.9 15.9 5.7 5.5 
4 I 13253 4        17.8       15.9 6.1          5.1 
5 H 72446 5        15.5        13.4 5.1 4.4 
6 I 39455 6 14.6 15.1 5.0 5.2 
7 I 41903 7 17.1 17.0 5.8 5.8 
8 H 80572 8 15.5        15.3 6.0 5.7 
9 H 70447 9 14.2 13.6 5.4 5.2 
10 I 44256 10        15.5 14.9 5.2 5.0 
11 I 25653 11 15.7 14.7 5.3 5.5 
12 I 44516 12 14.8 13.9 4.5 4.3 
13 I 16233 13 16.1 15.2 5.9 5.4 
14 I 26113 14 17.6 16.3 5.8 5.4 
15 I 46152 15 16.0 15.9 5.8 5.8 
16 I 22106 16 16.2 15.2 4.8 4.7 
17 F 042735 17 15.6 15.5 5.3 5.3 
18 I 43772 18 14.5 15.5 4.9 5.0 
19 I 46949 19 15.6 16.1 5.2 5.3 
20 I 08792 20 16.7 15.7 5.5 5.7 
21 I 17148 21 17.1 16.0 5.5 5.1 
22    I 49209 22 16.7 15.7 5.8 5.4 
23 I 46480 23 15.6 14.5 6.2 6.5 
24 I 47208 24 13.4 14.3 3.9 4.2 
25 I 48840 25 15.5 15.1 5.3 5.1 
26 I 48490 26 16.8 15.8          5.7 5.6 
27 I 29302 27 15.5 15.1 5.3 5.2 
28 I 46426 28 17.1 16.6 6.2 6.1 
29 H 86837 29 13.9 14.4 4.4 4.5 
30 I 31859 30 16.4 15.4 5.5 5.3 
31 I 51222 31 15.8 14.7 5.2 5.3 
32 I 47764 32 15.3 16.0 5.0 5.2 
33 I 53634 33 14.5 14.0 5.2 5.0 
34 I 53597 34 16.7 15.7 5.3 5.0 
35 I 52874 35 16.8 15.8 5.5 5.4 
36 I 46955 36 14.2 13.5 4.8 4.7 
37 H 74380 37 15.3 14.2 5.0 5.2 
38 I 55296 38 15.6 16.0 5.5 5.7 
39 I 22884 39 17.3 18.5 6.11   6.0 
40 I 53967 40 17.0 17.8 5.6 5.7 
 
 
 
 
 
BLOOD INVESTIGATION 
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SL.NO OP NO 
TotalWBCcount 
(million/cu.mm) 
DC % 
Before 
Treatment 
After 
Treatment 
NEUTROPHILS% LYMPHOCYTES% EOSINOPHILS% MONOCYTES% 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1 I 42978 9200 9000 66 60 27 31 - - 07 09 
2 I 42957 5800 5600 54 53 42 43 - - 04 04 
3 G 95889 8900 8700 56 55 37 38   07 07 
4 I 13253 6300 6100 50 52 46 44   04 04 
5 H 72446 6200 5400 68 50 26 42   06 08 
6 I 39455 8200 6400 68 59 26 35   06 06 
7 I 41903 7900 8100 65 69 30 26   05 05 
8 H 80572 6700 6600 60 55 32 37   08 08 
9 H 70447 8200 8600 65 64 30 31   05 05 
10 I 44256 7400 6300 64 60 32 36   04 04 
11 I 25653 11400 10400 42 45 29 26 27 27 02 02 
12 I 44516 6900 6500 70 75 25 20   05 05 
13 I 16233 7700 6700 66 64 30 32   04 04 
14 I 26113 5900 6000 51 50 43 44   06 06 
15 I 46152 10100 10100 50 55 25 25 22 19 03 01 
16 I 22106 10300 9400 59 57 32 34   09 09 
17 F 042735 5300 5300 66 60 29 33   05 07 
18 I 43772 6700 6800 40 42 47 45 11 11 02 02 
19 I 46949 6600 7700 63 63 32 31   05 06 
20 I 08792 9600 9900 69 68 27 28   04 04 
 
 
 
 
 
 
 
BLOOD INVESTIGATION 
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SL.NO OP NO 
TotalWBCcount 
(million/cu.mm) 
Differential Count 
Before 
Treatment 
After 
Treatment 
NEUTROPHILS % LYMPHOCYTES% EOSINOPHILS% MONOCYTES% 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
21 I 17148 7000 5100 70 65 22 30   08 05 
22    I 49209 7300 6300 52 53 39 38   09 09 
23 I 46480 7900 8100 71 70 23 24   06 06 
24 I 47208 7200 7400 57 58 29 28   12 12 
25 I 48840 6100 6700 46 50 47 42   07 08 
26 I 48490 5500 6500 55 50 40 45   05 05 
27 I 29302 8200 7400 60 55 31 37   09 08 
28 I 46426 7900 6800 60 53 36 43   04 04 
29 H 86837 5800 5500 62 55 32 40   06 05 
30 I 31859 9000 8900 52 50 41 43   07 07 
31 I 51222 7300 7100 59 60 34 33   07 07 
32 I 47764 5600 5500 73 72 23 24   04 04 
33 I 53634 11600 7500 59 54 36 40   05 06 
34 I 53597 9400 8700 56 50 30 35  01 14 14 
35 I 52874 11800 11500 67 66 29 30   04 04 
36 I 46955 8700 8400 74 73 22 23   04 04 
37 H 74380 6900 6800 46 45 48 49   06 06 
38 I 55296 6900 7100 45 47 49 45   06 08 
39 I 22884 9900 8700 70 65 26 27   04 08 
40 I 53967 9100 9200 60 65 34 29   06 06 
 
 
 
 
 
 
 
BLOOD INVESTIGATION 
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SL.NO OP NO ESR ESR 
mm/1/2 Hr mm/1 Hr 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1 I 42978 10 10 20 22 
2 I 42957 2 2 4 4 
3 G 95889 2 2 4 4 
4 I 13253 2 2 4 4 
5 H 72446 2 4 4 8 
6 I 39455 4 2 8 6 
7 I 41903 2 2 4 4 
8 H 80572 2 2 4 4 
9 H 70447 16 12 32 24 
10 I 44256 2 4 4 8 
11 I 25653 2 2 4 4 
12 I 44516 2 2 6 4 
13 I 16233 8 8 16 16 
14 I 26113 2 2 4 4 
15 I 46152 2 2 4 6 
16 I 22106 6 6 12 12 
17 F 042735 10 4 22 8 
18 I 43772 8 4 16 8 
19 I 46949 4 2 8 4 
20 I 08792 2 2 4 4 
21 I 17148 4 14 8 30 
22    I 49209 2 2 4 4 
23 I 46480 10 10 22 22 
24 I 47208 4 4 10 10 
25 I 48840 2 2 4 4 
26 I 48490 2 2 4 4 
27 I 29302 2 4 4 8 
28 I 46426 4 4 8 8 
29 H 86837 4 8 8 16 
30 I 31859 4 4 8 8 
31 I 51222 2 2 4 4 
32 I 47764 6 7 12 14 
33 I 53634 4 10 10 20 
34 I 53597 4 6 8 12 
35 I 52874 2 8 4 16 
36 I 46955 12 8 26 16 
37 H 74380 10 8 20 16 
38 I 55296 2 8 4 16 
39 I 22884 2 2 4 4 
40 I 53967 2 2 4 4 
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SL.NO OP NO 
T.Cholesterol (mg/dl) HDL (mg/dl) LDL (mg/dl) VLDL (mg/dl) TGL (mg/dl) 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After Treatment Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1 I 42978 114 109 38 28 59 63 18 36 90 140 
2 I 42957 165 190 48 45 89 95 20 25 101 120 
3 G 95889 149 155 43 45 87 90 41 39 203 150 
4 I 13253 160 160 44 36 85 97 37 42 183 209 
5 H 72446 117 131 49 38 65 75 19 39 95 198 
6 I 39455 194 218 65 50 107 136 23  113 427 
7 I 41903 230 177 57 38 133 113 25 55 124 273 
8 H 80572 164 169 53 33 88 97 32  161 426 
9 H 70447 161 176 50 42 96 106 24 33 118 167 
10 I 44256 148 191 45 37 87 124 28 51 139 258 
11 I 25653 171 169 43 50 96 90 41 45 203 199 
12 I 44516 124 163 48 38 77 100 18 39 90 196 
13 I 16233 184 194 58 56 101 110 29 39 146 140 
14 I 26113 149 171 47 40 90 106 22 58 111 289 
15 I 46152 104 183 33 34 67 111 15  77 502 
16 I 22106 227 207 43 40 143 140 27 35 137 140 
17 F 042735 153 175 55 38 86 105 15 61 77 306 
18 I 43772 147 152 47 40 78 70 17 25 86 90 
19 I 46949 129 142 41 36 74 84 25 43 126 218 
20 I 08792 124 134 40 45 74 80 12 20 61 65 
 I 17148           
    I 49209           
 I 46480           
 I 47208           
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SL.NO OP NO T.Cholesterol (mg/dl) HDL (mg/dl) 
LDL (mg/dl) 
VLDL (mg/dl) TGL (mg/dl) 
  
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
21 I 17148 161 164 43 39 97 101 19 24 97 123 
22    I 49209 200 195 50 40 122 120 23 25 117 110 
23 I 46480 151 160 34 38 94 90 35 38 176 165 
24 I 47208 140 160 56 55 78 75 14 20 72 75 
25 I 48840 149 185 42 38 89 113 20 63 102 316 
26 I 48490 101 115 41 40 54 56 12 20 60 65 
27 I 29302 162 179 45 36 97 110 27 56 133 280 
28 I 46426 188 186 44 43 119 109 32 53 158 268 
29 H 86837 92 135 32 31 53 83 11 36 55 181 
30 I 31859 174 136 54 39 104 77 22 43 112 215 
31 I 51222 131 135 47 48 74 70 30 35 147 160 
32 I 47764 147 150 65 60 85 84 08 20 38 140 
33 I 53634 160 165 57 40 99 103 28 49 139 247 
34 I 53597 148 167 38 23 88 101 45 40 224 200 
35 I 52874 213 200 60 55 128 125 26 35 129 130 
36 I 46955 188 190 40 45 82 89 72 70 359 300 
37 H 74380 205 201 43 46 121 125 36 35 181 180 
38 I 55296 190 195 40 45 120 125 35 40 150 155 
39 
       
I 22884 196 116 37 37 50 73 37 53 186 268 
40 I 53967 138 145 39 45 81 90 30 35 150 155 
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SL.N 
O 
OP NO 
Serum Bilirubin (mg/dl) Glucose Profile mg/dl 
Direct Indirect Total Fasting Post prandial Random 
Before 
Treatm 
ent 
After 
Treatm 
ent 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
1 I 42978 0.8 0.2 1.6 1.0 2.4 1.2 69 100 71 140   
2 I 42957 0.2 0.2 0.4 0.6 0.6 0.8 80 90 119 130   
3 G 95889 0.3 0.3 0.4 0.5 0.7 0.8     62 110 
4 I 13253 0.4 0.4 0.6 0.7 1.0 1.1 63 101 67 108   
5 H 72446 0.3 0.3 0.4 0.4 0.7 0.7 80  90   107 
6 I 39455 0.4 0.4 0.4 0.8 0.8 1.2 79 124 140 127   
7 I 41903 0.5 0.7 1.3 2.0 1.8 2.7 68 96 86 139   
8 H 80572 0.2 0.2 0.3 0.5 0.5 0.7     79 95 
9 H 70447 0.3 0.3 0.4 0.4 0.7 0.7 72 108 129 155   
10 I 44256 0.2 0.3 0.3 0.7 0.5 1.0     76 97 
11 I 25653 0.2 0.2 0.3 0.5 0.5 0.7     74 87 
12 I 44516 0.5 0.6 0.7 1.3 1.2 1.9 81 95 116 119   
13 I 16233 0.3 0.3 0.3 0.7 0.6 1.0 83 93 112 120   
14 I 26113 0.5 0.6 0.9 1.2 1.4 1.8 80 110 60 111   
15 I 46152 0.3 0.5 0.5 1.0 0.8 1.5     84 123 
16 I 22106 0.4 0.3 1.0 0.7 1.4 1.0     58 110 
17 F 042735 0.3 0.3 0.4 0.6 0.7 0.9 76 104 88 115   
18 I 43772 0.3 0.3 0.2 0.5 0.5 0.8     89 100 
19 I 46949 0.3 0.7 0.7 0.5 1.0 1.2  110  111 78  
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SL.N 
O 
OP NO 
Serum Bilirubin (mg/dl) 
Glucose Profile mg/dl 
Direct Indirect Total Fasting Post prandial Random 
Before 
Treatm 
ent 
After 
Treatm 
ent 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
20   I 08792 0.3 0.3 0.7 0.5 1.0 0.8 72 83 84 95   
21 I 17148 0.1 0.4 0.3 0.7 0.4 1.1     71 110 
22    I 49209 0.2 0.3 0.4 0.5 0.6 0.8 70 90 92 110   
23 I 46480 0.3 0.2 0.5 0.6 0.8 0.8     101 110 
24 I 47208 0.3 0.3 0.4 0.5 0.7 0.8 70 80 129 125   
25 I 48840 0.3 0.2 0.4 0.5 0.7 0.7 80 109 75 140   
26 I 48490 0.6 0.4 0.8 0.7 1.4 1.1     77 87 
27 I 29302 0.3 0.4 0.6 0.8 0.9 1.2 84     104 
28 I 46426 0.5 0.4 1.2 0.7 1.7 1.1 69  113   123 
29 H 86837 0.6 0.4 0.9 0.8 1.5 1.2 60 95 69 110   
30 I 31859 0.2 0.4 0.3 0.5 0.5 0.9     69 129 
31 I 51222 0.4 0.4 0.9 0.8 1.3 1.2 69 75 58 110   
32 I 47764 0.8 0.8 1.2 0.4 2.0 1.2     69 75 
33 I 53634 0.2 0.2 0.2 0.3 0.4 0.5  117  189 78  
34 I 53597 0.3 0.5 0.8 1.1 1.1 1.6     76 93 
35 I 52874 0.2 0.3 0.5 0.6 0.7 0.9 63 70 71 90   
36 I 46955 0.3 0.3 0.3 0.5 0.6 0.8     126 130 
37 H 74380 0.3 0.3 0.5 0.7 0.8 1.0 108 100 111 120   
38 I 55296 0.3 0.3 0.6 0.7 0.9 1.0 105 100 120 125   
39 I 22884 0.4 0.4 0.4 0.7 0.8 1.1     91 160 
40 I 53967 0.3 0.3 0.4 0.5 0.7 0.8 106 90 107 110   
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SL. 
NO 
OP NO SGOT (IU/L) SGPT (IU/L) serumAlkaline 
phosphatase (IU/L) 
SerumAlbumin 
(gms/dl) 
SerumGlobulin 
(gms/dl) 
SerumTotal 
Protein (gms/dl) 
Before 
Treatm 
ent 
After 
Treatm 
ent 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
1 I 42978 27 40 28 86 65 56 4.7 4.6 3.3 3.2 8.0 7.8 
2 I 42957 34 30 55 50 78 80 4.9 4.5 2.7 2.9 7.6 7.4 
3 G 95889 25 20 33 30 69 60 4.7 4.2 3.1 3.2 7.8 7.4 
4 I 13253 18 24 16 47 86 87 4.7 4.5 2.6 2.5 7.3 7.0 
5 H 72446 19 51 14 132 60 43 4.6 4.6 3.0 2.6 7.5 7.2 
6 I 39455 21 31 19 60 100 93 4.6 4.7 3.0 2.7 7.6 7.4 
7 I 41903 23 82 27 187 61 70 4.5 4.3 2.6 2.9 7.1 7.2 
8 H 80572 13 61 15 182 46 44 4.6 4.4 3.1 3.0 7.7 7.4 
9 H 70447 49 35 71 69 94 91 4.4 4.5 3.5 3.4 7.9 7.9 
10 I 44256 26 143 47 462 92 72 4.7 4.6 2.9 2.9 7.6 7.5 
11 I 25653 20 30 19 29 87 80 4.5 4.4 3.0 3.0 7.5 7.4 
12 I 44516 17 14 16 307 40 42 4.3 4.4 3.1 3.0 7.4 7.4 
13 I 16233 20 30 21 20 81 80 4.0 4.0 3.0 3.4 7.0 7.4 
14 I 26113 26 50 51 146 79 64 4.9 4.7 2.5 2.4 7.4 7.1 
15 I 46152 19 63 22 129 54 60 7.4 4.8 3.3 3.4 7.7 8.2 
16 I 22106 22 23 26 30 97 90 4.2 4.0 3.0 3.4 7.2 7.4 
17 F 042735 24 29 20 34 76 70 4.2 4.4 2.6 3.3 6.9 7.0 
18 I 43772 18 20 11 35 79 90 4.5 4.0 3.7 3.4 8.2 7.4 
19 I 46949 18 46 18 129 61 44 4.2 4.5 2.4 2.6 6.6 7.0 
20 I 08792 16 18 19 25 40 60 4.7 4.7 2.7 2.7 7.4 7.4 
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SL.N 
O 
OP NO SGOT (IU/L) SGPT (IU/L) serumAlkaline 
phosphatase (IU/L) 
SerumAlbumin 
(gms/dl) 
SerumGlobulin 
(gms/dl) 
SerumTotal 
Protein (gms/dl) 
Before 
Treatm 
ent 
After 
Treatm 
ent 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
Before 
Treatme 
nt 
After 
Treatme 
nt 
21 I 17148 20 22 20 35.4 80 65 4.5 4.8 3.0 2.8 7.5 7.6 
22    I 49209 21 20 34 40 78 81 4.6 4.0 2.9       3.4 7.5 7.4 
23 I 46480 14 15 21 25 59 60 4.4 4.2 3.0 3.2 7.4 7.2 
24 I 47208 20 25 20 40 79 85 4.7 4.8 3.6 3.5 8.3 8.3 
25 I 48840 23 19 29 35 106 88 4.4 4.5 2.7 2.6 7.1 7.1 
26 I 48490 21 25 35 36 54 60 4.7 4.0 2.5 3.0 7.2 7.4 
27 I 29302 23 69 36 131 76 65 4.4 4.5 2.6 2.5 7.0 7.1 
28 I 46426 18 12 19 25 71 53 4.3 4.6 3.5 3.0 7.8 7.6 
29 H 86837 18 84 22 308 82 92 4.5 4.5 2.5 2.7 7.0 7.2 
30 I 31859 18 25 32 50 50 38 4.3 4.3 3.3 3.1 7.6 7.4 
31 I 51222 30 35 28 25 74 70 4.5 4.0 3.5 3.4 8.0 7.4 
32 I 47764 19 20 07 25 84 80 4.7 4.7 2.7 2.7 7.4 7.4 
33 I 53634 21 34 23 60 87 83 4.7 4.0 3.4 3.4 8.1 7.4 
34 I 53597 17 87 23 26 65 60 4.6 4.4 2.9 2.7 7.5 7.1 
35 I 52874 20 21 38 30 101 90 4.4 4.3 3.6 3.7 8.0 8.0 
36 I 46955 20 25 33 30 85 80 4.3 4.0 2.8 3.3 7.1 7.3 
37 H 74380 20 15 27 30 59 65 4.4 3.5 3.2 4.0 7.6 7.5 
38 I 55296 20 25 35 36 40 50 4.0 4.0 3.4 3.2 7.4 7.2 
39 I 22884 15 41 37 96 82 83 4.5 4.6 2.7 2.6 7.2 7.2 
40 I 53967 24 30 31 25 87 90 4.4 4.2 2.9 2.5 7.3 7.2 
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SL. 
NO 
OP NO 
UREA mg/dl CREATININE mg/dl URIC ACID mg/dl 
Before 
Treatmen 
t 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1 I 42978 16 15 0.9 1.0 6.6 7.9 
2 I 42957 20 25 0.9 1.1 5.7 6.0 
3 G 95889 14 18 1.0 1.1 4.6 4.4 
4 I 13253 19 18 0.9 0.9 5.7 6.7 
5 H 72446 18 18 1.0 1.0 5.5 7.3 
6 I 39455 12 12 0.9 1.0 5.1 6.0 
7 I 41903 12 14 0.9 1.0 6.1 6.5 
8 H 80572 18 15 0.9 0.9 4.0 5.2 
9 H 70447 18 15 0.9 0.9 7.4 7.4 
10 I 44256 28 21 0.9 0.7 4.8 5.7 
11 I 25653 15 17 0.9 1.0 6.1 6.5 
12 I 44516 16 20 1.0 1.0 4.6 4.8 
13 I 16233 18 19 0.9 1.0 4.5 4.7 
14 I 26113 13 14 1.2 1.2 5.2 5.9 
15 I 46152 33 19 0.9 1.0 5.0 6.2 
16 I 22106 17 18 1.0 1.0 6.4 7.4 
17 F 042735 18 17 1.1 1.2 3.4 3.7 
18 I 43772 20 25 0.9 1.0 5.4 5.5 
19 I 46949 16 23 1.0 1.0 6.7 7.9 
20 I 08792 17 18 1.0 1.0 6.5 6.4 
21 I 17148 14 31 0.9 0.9 5.8 7.1 
22    I 49209 17 19 1.2 1.2 6.9 6.5 
23 I 46480 19 21 1.1 1.1 7.2 7.0 
24 I 47208 10 18 0.8 0.7 2.7 2.8 
25 I 48840 19 25 0.9 1.0 5.0 5.6 
26 I 48490 36 37 0.9 1.0 4.7 4.5 
27 I 29302 20 19 1.0 1.0 5.4 6.9 
28 I 46426 18 33 1.0 1.2 6.1 6.9 
29 H 86837 37 20 0.9 1.0 5.4 6.5 
30 I 31859 18 16 1.1 1.2 6.7 8.0 
31 I 51222 16 20 0.9 1.0 5.3 5.4 
32 I 47764 31 30 0.9 1.0 3.6 3.5 
33 I 53634 15 25 1.0 0.9 7.4 7.3 
34 I 53597 17 23 1.2 1.11 6.1 6.8 
35 I 52874 17 18 1.0 1.2 6.0 6.8 
36 I 46955 13 16 0.8 0.9 7.3 7.2 
37 H 74380 14 16 0.9 1.0 5.6 5.5 
38 I 55296 16 20 1.0 1.2 5.5 5.4 
39 I 22884 18 19 1.2 1.2 4.8 6.4 
40 I 53967 17 18 1.0 1.2 6.4 6.3 
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SL.N 
O 
OP NO 
Sperm Count/ml Motility % Morphology% 
Before 
Treatme 
nt 
After 
Treatmen 
t 
Before 
Treatme 
nt 
After 
Treatmen 
t 
Before 
Treatme 
nt 
After 
Treatmen 
t 
1 I 42978 30 130 30 70 40 90 
2 I 42957 38 50 20 50 40 60 
3 G 95889 8 30 10 30 40 40 
4 I 13253      14 110 10 10 40 50 
5 H 72446 40 100 40 45 40 50 
6 I 39455 30 35 10 10 90 90 
7 I 41903 13 18 20 22 94 95 
8 H 80572 3 110 10 10 50 90 
9 H 70447 37.5 80 05 10 90 90 
10 I 44256 4.2 19.2 30 40 40 60 
11 I 25653 30 80 40 50 40 50 
12 I 44516 12 20 10 15 40 50 
13 I 16233 18 80 40 55 50 50 
14 I 26113 1 100 40 50 50 50 
15 I 46152 40 45 30 40 50 50 
16 I 22106 30 60 10 10 50 50 
17 F 042735 12 110 20 80 40 90 
18 I 43772 20 45 40 55 90 90 
19 I 46949 2.1 50 05 10 90 90 
20 I 08792 33 40 30 30 90 90 
21 I 17148 20 55 30 70 40 90 
22    I 49209 25 90 10 15 90 90 
23 I 46480 32 45 10 20 50 50 
24 I 47208 39 60 30 35 40 60 
25 I 48840 11 70 30 60 60 60 
26 I 48490 7 15 10 10 40 40 
27 I 29302 21 25 10 10 20 20 
28 I 46426 8.0 62.8 20 53 30 76 
29 H 86837 4 50 10 60 20 50 
30 I 31859 34 120 40 50 60 60 
31 I 51222 6 10 10 10 40 40 
32 I 47764 14 20 20 30 40 40 
33 I 53634 26 12 30 10 40 40 
34 I 53597 26 32 30 10 40 40 
35 I 52874 6 45 40 55 10 60 
36 I 46955 30 110 30 60 78 80 
37 H 74380 35 60 40 55 55 60 
38 I 55296 20 60 30 60 40 60 
39 I 22884 35 110 20 50 40 80 
40 I 53967 28 60 30 55 50 70 
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Sl. 
No 
OP NO 
Volume ml Liquefaction Time 
(mints) 
Fructose 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1 I 42978 1.5 2.0 20 20 PRESENT PRESENT 
2 I 42957 1.0 2.0 30 30 PRESENT PRESENT 
3 G 95889 1.0 2.0 30 30 PRESENT PRESENT 
4 I 13253 2.0 3.0 30 30 PRESENT PRESENT 
5 H 72446 1.5 2.5 20 30 PRESENT PRESENT 
6 I 39455 1.5 1.0 30 30 PRESENT PRESENT 
7 I 41903 2.2 5.1 30 25 PRESENT PRESENT 
8 H 80572 1.5 2.0 20 30 PRESENT PRESENT 
9 H 70447 1.5 4 30 30 PRESENT PRESENT 
10 I 44256 6.5 5.9 30 30 PRESENT PRESENT 
11 I 25653 1 2.5 20 30 PRESENT PRESENT 
12 I 44516 1.5 1.5 30 30 PRESENT PRESENT 
13 I 16233 2.0 2.5 30 20 PRESENT PRESENT 
14 I 26113 2.0 3 30 35 PRESENT PRESENT 
15 I 46152 2.5 3.0 20 15 PRESENT PRESENT 
16 I 22106 3.5 3 30 30 PRESENT PRESENT 
17 F 042735 1 1 30 30 PRESENT PRESENT 
18 I 43772 1.5 2 40 40 PRESENT PRESENT 
19 I 46949 1.5 2.0 30 30 PRESENT PRESENT 
20 I 08792 2.0 2.5 25 25 PRESENT PRESENT 
21 I 17148 1.5 2.5 30 20 PRESENT PRESENT 
22    I 49209 4.0 2.5 30 30 PRESENT PRESENT 
23 I 46480 2 2.5 30 30 PRESENT PRESENT 
24 I 47208 2.5 6.5 20 8 PRESENT PRESENT 
25 I 48840 4 1.5 30 30 PRESENT PRESENT 
26 I 48490 2 2.5 30 30 PRESENT PRESENT 
27 I 29302 1.5 2.5 30 30 PRESENT PRESENT 
28 I 46426 1.5 2 30 35 PRESENT PRESENT 
29 H 86837 2 3 30 20 PRESENT PRESENT 
30 I 31859 3 2.2 30 30 PRESENT PRESENT 
31 I 51222 1.5 2.5 20 30 PRESENT PRESENT 
32 I 47764 1.5 2.5 20 30 PRESENT PRESENT 
33 I 53634 1.5 1 30 30 PRESENT PRESENT 
34 I 53597 1.5 4 30 30 PRESENT PRESENT 
35 I 52874 1.5 2.5 30 30   PRESENT     PRESENT 
36 I 46955 1.5 2.5 30 30 PRESENT PRESENT 
37 H 74380 2.5 3 30 30 PRESENT PRESENT 
38 I 55296 2.5 3 30 30 PRESENT PRESENT 
39 I 22884 2 1 30 30 PRESENT PRESENT 
40 I 53967 1.5 3 20 30 PRESENT PRESENT 
 
 
 
 
 
 
 
SEMEN ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
SL.N 
O 
OP NO 
URINE 
Before Treatment After Treatment 
Albumin Sugar 
Deposits 
Albumin Sugar 
Deposits 
Pus Cells Epi Cells Pus Cells Epi Cells 
1 I 42978 NIL NIL 02-3cells 02-4 cells NIL NIL 02-4 cells 03-4 cells 
2 I 42957 NIL NIL 02-3cells 02-4 cells NIL NIL 02-4 cells 02-4 cells 
3 G 95889 NIL NIL 03-4 cells 03-3 cells NIL NIL 02-4 cells 02-4 cells 
4 I 13253 NIL NIL 02-4 cells 02-3 cells NIL NIL 03-3 cells 02-4 cells 
5 H 72446 NIL NIL 02-4 cells 02-3cells NIL NIL 02-4cells 03-3 cells 
6 I 39455 NIL NIL 02-4 cells 03-4 cells NIL NIL 02-3cells 02-4 cells 
7 I 41903 NIL NIL 03-3 cells 02-4 cells NIL NIL 02-3cells 02-4 cells 
8 H 80572 NIL NIL 02-3 cells 02-4 cells NIL NIL 03-4 cells 02-4 cells 
9 H 70447 NIL NIL 02-3cells 02-4 cells NIL NIL 02-4 cells 03-3 cells 
10 I 44256 NIL NIL 03-4 cells 03-3 cells NIL NIL 02-4 cells 02-4 cells 
11 I 25653 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-4 cells 02-4 cells 
12 I 44516 NIL NIL 02-4 cells 02-4 cells NIL NIL 03-3 cells 02-4 cells 
13 I 16233 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-3 cells 03-3 cells 
14 I 26113 NIL NIL 03-3 cells 03-3 cells NIL NIL 02-3cells 02-4cells 
15 I 46152 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-4 cells 02-3cells 
16 I 22106 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-4 cells 02-3cells 
17 F 042735 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-4 cells 03-4 cells 
18 I 43772 NIL NIL 03-3 cells 03-3 cells NIL NIL 03-3 cells 02-4 cells 
19 I 46949 NIL NIL 02-4 cells 02-4cells NIL NIL 02-4cells 02-4 cells 
20 I 08792 NIL NIL 02-4 cells 03-3 cells NIL NIL 02-3cells 02-4 cells 
21 I 17148 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-3cells 03-3 cells 
22    I 49209 NIL NIL 03-3 cells 02-4 cells NIL NIL 03-4 cells 02-3 cells 
23 I 46480 NIL NIL 02-4cells 02-4 cells NIL NIL 02-4 cells 02-3cells 
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SL.N 
O 
OP NO 
URINE 
Before Treatment After Treatment 
Alb 
umi 
n 
Sugar 
Deposits 
Albumin Sugar 
Deposits 
Pus Cells Epi Cells 02-3 cells Epi Cells 
24 I 47208 NIL NIL 02-3cells 02-4 cells NIL NIL 02-3cells 02-4 cells 
25 I 48840 NIL NIL 02-3cells 02-4 cells NIL NIL 02-4 cells 03-3 cells 
26 I 48490 NIL NIL 03-4 cells 03-3 cells NIL NIL 02-4 cells 02-4 cells 
27 I 29302 NIL NIL 02-4 cells 02-3 cells NIL NIL 02-4 cells 02-4 cells 
28 I 46426 NIL NIL 02-4 cells 02-3cells NIL NIL 03-3 cells 02-4 cells 
29 H 86837 NIL NIL 02-4 cells 03-4 cells NIL NIL 02-4cells 03-3 cells 
30 I 31859 NIL NIL 03-3 cells 02-4 cells NIL NIL 02-3cells 02-4 cells 
31 I 51222 NIL NIL 02-3 cells 02-4 cells NIL NIL 02-3cells 02-4 cells 
32 I 47764 NIL NIL 02-3cells 02-4 cells NIL NIL 03-4 cells 02-4 cells 
33 I 53634 NIL NIL 03-4 cells 03-3 cells NIL NIL 02-4 cells 03-3 cells 
34 I 53597 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-4 cells 02-4cells 
35 I 52874 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-4 cells 02-3cells 
36 I 46955 NIL NIL 02-4 cells 02-4 cells NIL NIL 03-3 cells 02-3cells 
37 H 74380 NIL NIL 03-3 cells 03-3 cells NIL NIL 02-3 cells 02-3cells 
38 I 55296 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-3cells 02-3cells 
39 I 22884 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-3 cells 01-3 cells 
40 I 53967 NIL NIL 02-4 cells 02-4 cells NIL NIL 02-3cells 04-5 cells 
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DISCUSSION 
 There was a time when infertility was only limited to women but in present 
scenario male infertility is blamed in 59% of cases where couples could not conceive 
naturally. Most of the cases hail from IT back ground. The change in life style even 
among small income group has led to increase in infertility rate and lack of physical 
activities. . Any infections that occur at an early age in a male child and low economic 
standards can also lead to rise in male infertility.   
 The most common problems men face are low sperm count, low motility rate 
and morphological abnormalities. The reproductive age for men is 18 to 50  
Age Distribution 
Among 40 cases   
45% cases are between the age group of 24-29 yrs 
18%  cases are between the age group of 30-34 yrs 
25% cases are between the age group of 35-39 yrs 
12% cases are between the age group of 40-45 yrs  
Inference: 
In my study the prevalence of the disease was found to be more in the age 
growth ranging from 24years to 29years (45%) 
Occupational history 
Out of 40 patients 45% patients were working in hot atmosphere.IT Profession 
3Patients(7.5%),Electrician 15 Patients(37.5%)  working in hot atmosphere. This 
plays  an  vital role in male infertility. This may be one of the causes for infertility. 
Food habits  
Out of 40 patients 36(90%) were non vegetarian and 4(10%) were vegetarian. 
This dietary style is more prone for developing infertility 
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Personal habits 
Out of 40 patients 15 (37.5%) patients were smokers and Social drinkers. 
10(25%) patients were only smoker. 
15(37.5%) patients were with none of the above habits. 
Smoking is the major cause of male infertility because it increases the 
concentration of free radicals in the seminal fluid. 
Duration of Male Infertility 
50% of patients were within 3 years duration of infertility. 
25% of patients were within 4 years to 6 years of infertility. 
20% of patients were within 7years to 9 years of infertility. 
5% of patients were more than 10 years of infertility. 
 
Thinai 
           20% of patients came from Marutham thinai. 
5% of patients from Mullai thinai. 
           75% of patients from Neithal thinai. 
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Paruvakaalam 
100% of the patients came in munpanikaalam(Jan-Feb). The body which is 
already been  weak due to the effect of previous season .  
Thegi  
25% of patients presenting with Vatha Thegi. 
50% of patients presenting with Pitha Thegi. 
 25% of patients presenting with Kaba Thegi. 
Pitha thegi are more prone to male infertility. 
Three Humors 
In 50% of patients  Vatham (abannan) was affected.(pre mature ejaculation, 
burning micturition). 
In 100%of patients  Pitham  (Sathagam phitham) was affected. ( decreased 
sperm count). 
In 62.5% of patients Kabam (Tharpakam) was affected. (burning sensation of 
eyes). 
KOSAM (Five sheaths) 
In 100%of the patients Annamayakosam was affected. (Two of the physical 
constituents saaram and senner affected). 
80% of the patients ManomayaKosam was affected.(depression). 
100%of the patients AnandhamayaKosam was affected.(decreased sperm 
count and motility).   
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Udal Thathukkal 
Saram was affected in 100%  patients. 
Senneer was affected in 100% patients. 
Sukkilam was affected in 100% patients 
Derangement of Saaram, Senneer,sukkilam or any one of this lead to 
development of infertility.  
Envagai theryu 
 Naa -7.5% of patients presenting with Dryness of tongue. 
Sparisam – Sparisam was Veppam  in 32.5%patients  due to working in hot 
atmosphere. 
Sparism was Methavepam in 67.5%patients.  
Moothiram was affected in 42.5% patients ( burning micturition). 
Naadi -37.5% of the patients were presenting with Vatha Pitham Naadi. 
62.5% of the patients were presenting with Pitha Vatham Naadi. 
Sukkilam: 
Buoyancy on water :The important Siddha parameter to evaluate the Sperm.In 5% of 
the patients  sperm were floating on water indicating abnormal condition. 95% of the 
patients presented sperms not were floating on water indicating normal condition. 
Neerkuri 
The important Siddha diagnostic parameter. 
30% of patients the colour of the urine was pale yellow colour. 
10% of the patients the colour of the urine was colour. 
10% of the patients the colour of the urine was dark yellow in colour. 
50% of the patients the colour of the urine was straw coloured urine. 
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Neirkuri 
 An important Siddha parameter reflecting the signs of Prognosis is spreading pattern 
of the in the urine . 
10% of patients the Nei kuri showed slowly spread pattern. 
75% of patients the Nei kuri showed fastly spread pattern. 
15%% of patients the Nei kuri showed Stand still(No spread) 
History of Masturbation 
Masturbation habit was present in 40 patients Out of these 75% were within  5 
years duration.  25% were above 5 years to 10 years duration.  
In all the 40 patients the frequency of masturbation was once in 2 days or 
weekly twice. 
Clinical Features     
Premature ejaculation is the commonest symptom in  infertility patients. 75% 
of patients suffered with this complaint. These patients were not fully satisfied during 
intercourse. 70% the patients were improved after the treatment. 
87.5% Patients came with erectile dysfunction , but not persistent. All the 80% 
patients improved after the treatment .  sometimes  premature ejaculation and erectile 
dysfunction may be associated with painful coitus. 
12.5%Patients came with painful micturition.7.5% the patients were 
improvement after treatment. 
Nocturnal emission is another important feature in infertility. Recurrent 
emission leads to decreased sperm count and motility. 25% patients came with this 
complaint, among them 20% were improved after the treatment. 
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Semen analysis- Semen Count After treatment improvement profile 
5% of patients improved after treatment within 5 Million / ml 
5% of patients improved after treatment more than 5Million to 10Million. 
10% of patients improved after treatment more than 11Million to 20Million. 
20% of patients improved after treatment more than 21Million to 30Million 
60% of patients improved after treatment more than 30 Million  
 
Semen analysis -   Active Motility After treatment improvement profile 
15% of patients improved after treatment with Active Motility less than 5% 
25% of patients improved after treatment with Active Motility more than 5% 
to 10%. 
20%of patients improved after treatment with Active Motility more than 11% 
to 20%. 
2.5% of patients improved after treatment with Active Motility more than 21% 
to30%. 
37.5%of patients improved after treatment with Active Motility more than 
30%. 
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PRIMARY OUTCOME OF THE TREATMENT WITH THE 
TRAIL DRUG POONAKALI VITHAI CHOORNAM 
Primary out come regarding sperm count 
50.5% of the patients falling into the category GOOD- increase of sperm 
count with range of 40-60Million/ml. 
12.5% of the patients falling into the category MODERATE- increase of 
sperm count with range of 40 to more than 50Million/ml. 
12.5% of the patients falling into the category MILD- increase of sperm count 
with range of 40-upto 50Million/ml.  
24.5% of the patients falling into the category POOR- with the range of sperm 
count below 40Million/ml.  
Primary out come regarding Active Motility 
24% of the patients falling into the category GOOD- increase of Active 
Motility  with range of 50%-70%. 
41% of the patients falling into the category MODERATE- increase of Active 
Motility  with range of 50 %to 60%. 
10% of the patients falling into the category MILD- increase of Active 
Motility  with range of with 50%. 
25% of the patients falling into the category POOR-   with range of Active 
Motility  within  50%. 
In clinical study , out of 40 patients 37 patients were showed improvement in 
clinical lab investigation(semen analysis). The sperm count and sperm motility were 
improved in those patients. All the 37  patients  were relived from clinical symptoms. 
The sperm count and sperm motility differences before and after treatment 
showed  statistically significant in Male infertility patients. 
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STATISTICAL ANALYSIS: 
BIO STATISTICAL ANALYSIS 
The effectiveness of the clinical trialdrug Poonaikali vithai choornam was 
assessed by using paired comparison test (paired t test). The responses regarding 
sperm count and motility   of the patients to the drug are analyzed 
Assessment of the effectiveness of drug: 
The effectiveness of the drug was assessed by the improvement of the patients 
from low sperm count, low motility which is measured using assessment score. 
Inference: The test drug is statistically significant (p>0.0001) and hence it is 
effective in the treatment of Aanmaladu. 
 
BIOCHEMICAL ANALYSIS: 
 Preliminary Biochemical analysis of poonaikali vithai choornam was done in 
NIS biochemical analysis showed the presence of minerals like,chloride, 
carbonate, iron, calcium, ammonium, potassium. 
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TOXICITY STUDY: 
ACUTE TOXICITY: 
Acute toxicity studies done in C.L.Baid Meyha college as per OECD guide 
lines revealed the safety of the drug in oral single doses(2000mg) it did not produce 
any adverse effects in the animals. There were no abnormalities detected in the 
internal organs on necropsy.  
(28 days)REPEATED ORAL TOXICITY:  
28 days Repeated oral toxicity studies done in National Institute of Siddha, as 
per OECD guide lines did not reveal any adverse effects in the animal. Animal 
behavior, metabolic functions (food and water intake, defecation, urination etc) did 
not reveal any abnormality. Blood investigation parameters and histopathological 
examination did not show any abnormal variations. 
Hence it can be concluded from the study that up to maximum dose (2000   
mg/animal) the drug was proved to be safe. 
There were no side effects were observed during the course of treatment and 
after treatment also. 
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           SUMMARY  
In developing country like India ,one in every  four couples found to be 
affected by infertility. In 2010 almost 50 million couples world wide unable to have a 
child after five years of marriage. Infertility rate has hardly changed over the past 20 
years.The global health community has made great success in improving the infertility 
care in the past decade. Infertility can lead to distress and depression as well as 
discrimination and ostracism. infertility can be caused by poor sexual life style habits 
that are easily remedied. Heavy usage of alcohol, tobacco  drugs, tight underwares or 
pants which raise the scrotal temperature and reduce the sperm count. Infections play 
an vital role in male infertility that block the ducts through which  the sperm travels. 
Exposure to metals such as lead, chemical and pesticide plays a major role in male 
infertility.Auto immunity in which antibodies or cells of the human immune system 
attack sperm cells mistaking them as toxic invaders. Now a days male infertility 
treatmeant is a challenging task. In recent years  siddha system of medicine have 
bloomed up in treating male infertility with high success rate.  
The main aim of this study is to document the effectiveness of siddha 
medicine poonaikali vithai choornam (Internal medicine) in the management of 
AANMALADU (Male infertility). 
The objective of this study is the Preclinical and Clinical Studies .Preclinical 
studies consist standardisation and safety of the study of drug.Clinical studies 
conducted in 40 cases. 
The raw drug were purchased from reputed country medical shop in Chennai 
and drug authentication by Botanical of NIS. 
The drug was prepared as per standard operating procedure mentioned in the 
siddha literature in Gunapadam laboratory of National Institute of Siddha.  
The standardization of study drug was carried out in the Biochemistry lab of 
NIS.It revealed the presence of  chloride, fluoride, carbonate with the study drug.  
The preclinical toxicity studies (Acute and repeated oral 28 days toxicity) for 
the above said study drug was conducted at Pharmacology laboratory, C.L.Baid 
Metha college (IAEC NO: IAEC/XLIX/13/CLBMCP/2016).  
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The study drug was found to the usage as per the data generated from the 
studies.  
The histopathological studies did not reveal any abnormalities in the animals 
in both control and test group revealed that the drug was non-toxic. 
The clinical study was conducted with a well defined protocol and a proper 
proforma after getting the approval of the Institutional Ethical Committee. (IEC 
NO:NIS/IEC/9/2014-15/7-26.08.2015. 
The study data were registered in CTRI ( Clinical Triall Registry of India) 
with ID NO: CTRI/2016/07/011882. 
After screening 60 cases study based on the inclusion criteria and exclusion 
criteria reporting at the OPD of Maruthuvam , 40 cases were selected for induction to 
the study. Before enrolment into the trial the informed consent was obtained from the 
patients. 
The aim of the study is to increase the sperm count and sperm motility in male 
infertility patients. The duration of administration of study drug 48 days. The study 
drug dose was 6grams twice a daily with cow ghee. 
           Before Starting the treatment semen analysis, routine blood and urine 
examination were taken in all 40 patients. Siddha methods like three Humor, Thegi, 
Kosangal, udal thathukkal, Envagai thervu,neeikuri, nerkuri and buoyancy of Semen 
on water were analysed in all 40 Cases.Out of 40 Patients 30 Patients Presence with 
following Symptoms Premature ejaculation, Erectile dysfunction, Painful micturition, 
Nocturnal emission.The remaining 10 Patients were symptoms free but their clinical 
lab semen analysis report showed low sperm count and motility problem  with  The 
entire details were noted in the selection proforma. 
Patients were instructed to come for clinical once in 12 days. They were also 
instructed to bring back the unconsumed drug during the next visit and return the 
same.In every visit the clinical assessment was made. 
             At the end of the treatment reduction of clinical symptoms and improvement 
in clinical lab para meters (Sperm count and motility)in all the 40 patients.  
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Improvement in the Sperm count with in 5 million and more than 5 to 10 million were 
report in cases each 5%. More than 11 to 20 million was found in cases 10%. More 
than 21 to 30 million was found in 20% of cases. More than 30 million was reported 
in 60% of cases. 
 Improvement in the active motility with the range of 50%-70% in 24% of cases. 
50%-60% in 41% of cases. 50% in 10% of cases. Lessthan 50% in 25% of cases were 
observed. 
                30patients complaining regarding secondary sexual characters showed 
improvement. 18 patients attained the stage of fertilization. After the treatment no side 
effects were noted.           
The cost of medicine is comparatively low. The ingredients were easily 
available and the rural people will be benefited more. 
I have concluded the siddha medicine Poonaikali vithai choornam was 
effective in treatment of ―Aan maladu‖  ( Male infertility especially oligospermia and 
asthenozoospermia). 
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                                  CONCLUSION 
The trail drug POONAIKALI VITHAI CHOORNAM on administrating to 40 
patients for 48days have improved the quality of semen  in count and motility.  
The safety studies (Acute toxicity and repeated oral toxicity) studies conducted 
revealed that the study drug was safe even at higher dosage of 2000 mg/kg body 
weight in Wistaralbino rats as per OECD guideline-423  
Expenditure of the study drug is cost effective, easily preparable and highly effective 
in Aan maladu. 
Sperm Count: (Ref: As per 1999 WHO criteria)                                               
      Sperm count have improved to Good result by 50.5% 
Sperm count have improved to Moderate by 12.5% 
Sperm count have improved to Mild by 12.5% 
Sperm count falling with the Poor criteria by 24.5% 
 
 Sperm Motolity: (Ref: As per 1999 WHO criteria) 
      Sperm motility have improved to Good result by 24% 
Sperm motility have improved to Moderate by 41% 
Sperm motility have improved to Mild by 10% 
Sperm motility falling with the Poor criteria by 25% 
 
 Initially 50% of patients were affected from secondary sexual characters like 
premature ejaculation,erectile dysfunction,nocturnal emission,Painful 
micturition.Among them 44.4% were improved after the treatment. 
 No adverse drug reactions were noticed during the course of treatment 
 Because of the encouraging clinical and laboratory results, the study may be 
undertaken with the same medicines for a prolonged period in a large number 
of cases for the treatment of Aan maladu.     
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                             NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
                                         AYOTHIDOSS PANDITHAR HOSPITAL 
                    DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AAN MALADU ” (MALE INFERTILITY) 
AND THE DRUG OF CHOICE IS “POONAIKALI VITHAI CHOORANAM”  
   FORM I  SCREENING & SELECTION PROFORMA 
 REG NO:  
1. STUDY  NO______    2 OP NO:__________ 
 
3.NAME :______________________________ 4. AGE/SEX________5.RELIGION : H / C / M / O 
 
6.OCCUPATION / INCOME : ____________ 
 
 INCLUSION CRITERIA 
1. Male infertility 
2. Age  21- 45 year 
3. Maritial status -  more than 1 year 
4. Sperm count <40 Millions/Ejaculation 
5. Motility less than < 50 % 
6. Patient willing to sign the informed consent stating that he  will conscientiously stick to the 
treatment during 48days but can opt out of the trial of his  own conscious discretion. 
7. Patients who are willing to give specimen of blood , urine and semen before and after the 
treatment 
EXCLUSION CRITERIA 
1. Azoospermia 
2. Hydrocele 
3. Diabetes mellitus 
4. Endocrine disorders 
5. Hypertension 
6. Caridiac diseases 
7. VDRL & STD 
8. Inguinal Hernia 
9. Renal diseases 
10. Varicose veins 
11. Systemic illness 
ADMITTED TO TRAIL :    YES         NO         If Yes Serial NO:  
Date: 
 
Station: 
                                                                                     
Signature of  the Investigator:                                                        
 
Signature of the Lecturer:      
         
        Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AAN MALADU ” (MALE INFERTILITY) AND THE 
DRUG OF CHOICE IS “POONAIKALI VITHAI CHOORANAM” 
FORM lI CLINICAL RESEARCH FORM 
REG NO:  
1. Study  No :________________   2. OP No:________________________________ 
       
3. Name: ___________________________________  4. Gender: Male 
 
5. Age (years): _______________DOB            
      Date       Month            Year 
6.Address:______________________________ _______________________________ 
                  ______________________________ _______________________________ 
 
7.A.Occupation:--------------------------------    B. Nature of work--------------------------- 
 
8. Educational  Status: A) Illiterate        B)Literate        9.Marital status-     
   
10. Complaints and Duration:   
________________________________________________________________________ 
 
________________________________________________________________________ 
11. Habits of 
 
A) Smoking  1. Yes; duration ________ years; Number - 2.No 
B) Alcoholism  1. Yes; duration ________ years; Quantity-   ml 2.No 
C) Tobacco chewing 1. Yes; duration ________ years; 2.No 
D) Betel chewing 1. Yes; duration ________ years;   2.No 
E)Drugs addiction         1. Yes; duration ________ years;   2.No 
 
12.Dietary style A.Pure vegetarian           B.Non-vegetarian            C. Mixed diet 
 
13.Treatment  History:  
Had the patient been treated before with fertility drugs? A)Yes            B)No 
 
14.Previous history:     
Past Infertility history (Yes/No) 
             
            Past Medical history (Yes/No) 
 
Past Surgical history (Yes/No) 
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 SIDDHA SYSTEM OF EXAMINATION 
          
              
1. ENNVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
 
 I. NAADI: [PULSE PERCEPTION] 
     
 Naadi 0
th
 
day 
12
th 
Day
 
24
th 
Day
 
36
th 
Day 
48
th
 
Day 
Vali      
Azhal      
Iyyam      
Vali azhal      
Azhal vali      
Iyya vali      
Vali Iyyam      
Azhal Iyyam      
Iyya Azhal      
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II. NAA:[TONGUE] 
 
 
 
III.NIRAM: [COMPLEXION]    
 
 
IV.MOZHI: [VOICE] 
 
 
 
 
 
 
 
 
 
 
0th Day 12th Day 24th Day 36th Day 48th Day 
Colour Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Taste Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
0
th
 Day 12th day 24
th
 Day 36
th 
Day 48
th
 Day 
Dark/ 
Yellowtinted/ 
Wheatish 
brown/ Pale 
Dark/ 
Yellowtinted/ 
Wheatish 
brown/ Pale 
Dark/ 
Yellowtinted/ 
Wheatish 
brown/ Pale 
Dark/ 
Yellowtinted/ 
Wheatish 
brown/ Pale 
Dark/ 
Yellowtinted/ 
Wheatish 
brown/ Pale 
0
th
 Day 12th day 24
th
 Day 36
th 
Day 48
th
 Day 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Lowpitched 
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V.VIZHI: [EYES] (Lower palpabrel conjunctiva)   
 
 
   
 
 
 
 
 
VI. MALAM; [BOWEL HABITS / STOOLS] 
 
 0
th
 Day 12
th
 Day 24
th
 Day 36
th
 Day 48
th
 day 
Colour Dark/ 
Yellow/ 
Pale/Others 
Dark/ 
Yellow/ 
Pale/Others 
Dark/  
Yellow 
Pale/Others 
Dark/ 
Yellow/ 
Pale/Others 
Dark/  
Yellow/ 
Pale/Others 
Consistency Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Stool  bulk                          Normal/ 
Reduced 
Normal 
/Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diarrhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
 
 
 
0
th
 Day 12th day 24
th
 Day 36
th 
Day 48
th
  Day 
Yellow 
Red 
/ Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
NEER 
KURI 
0
th
 Day 12
th
 Day 24 
th
 Day 36
th
  Day 48
th
  day 
Niram 
[Colour]   
White/ 
Yellowish/ 
Straw 
coloured/ 
Crystal 
clear 
White/ 
Yellowish/ 
Straw coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw 
coloured/ 
Crystal clear 
Manam 
[Odour] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Nurai 
[Froth] 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai 
[Sp.gra]                                
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Enjal 
[Deposits] 
Present/ 
 Absent 
Present/ 
 Absent 
Present/ 
 Absent 
Present/ 
 Absent 
Present/ 
 Absent 
Volume   Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
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VII. URINE EXAMINATION:  
   
 
 
 
 
 
 
 
 
VIII. SPARISAM: [PALPATORY  PERCEPTION] 
 
0
th
 Day 12
th
 Day 24
th
 Day 36
th
 Day 48
th
 day 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
 
THEGI: [ TYPE OF BODY CONSTITUTION]  
   
Vatham predominant  Kabam predominant 
Pitham predominant  Thondha udal 
 
6.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
1.Kurinji        (Hilly terrain)   
2.Mullai         (Plains)                 
3.Marutham   (Forestrange)                 
4.Neithal        (Coastal belt)              
5.Palai            (Aridregions)     
 
                 
7.KAALAM 
 
Kaarkalam   Pinpanikalam      
Koothirkalam   Ilavenil 
Munpanikalam   Muthuvenil 
 
8. GUNAM 
Sathuvam                        Rasatham                       Thamasam 
 
NEIKURI 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Serpentine fashion      
Annular/Ringed 
fashion 
     
Pearl beaded fashion         
Mixed fashion      
Other fashion      
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IMPORIGAL (SENSORY ORGANS) 
 
 
 
KANMENTHIRIYAM ( MOTOR ORGANS) 
 
 
 
 
 
 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Mei  
(Skin) 
     
Vaai 
(Buccal 
Cavity) 
     
Kann 
 (Eye) 
     
Mooku 
(Nose) 
     
Sevi(Ear)      
Kanmenthiriyam  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Kai (upper limb)      
Kaal (lower limbs )      
Vaai   (buccal 
cavity) 
     
Eruvai (excretory 
organs) 
     
Karuvai  
(reproductive 
organs) 
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KOSANGAL(Sheath)    
 
Kosangal 
 
0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Annamaya Kosam 
 
     
Pranamaya kosam      
Manomaya kosam       
Vignanamaya kosam  
 
     
Ananthamaya kosam      
 
MUKKUTRAM:[AFFECTION OF THREE HUMORS] 
A)VATHAM: 
Vatham  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Praanan      
Abaanan      
Samaanan      
Udhaanan      
Viyaanan      
Naagan      
Koorman      
Kirukaran      
Devathathan      
Dhananjeyan      
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B) PITHAM: 
 
Pitham 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Analapitham      
Prasakam      
Ranjakam      
Aalosakam      
Saathakam      
 
C) KABAM: 
Kabam  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Avalambagam      
Kilethagam      
Pothagam      
Tharpagam       
Santhigam      
 
13. SEVEN DHATHUS: (7 SOMATIC COMPONENTS)  
 
 
 
Udal thathukkal  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Saaram[Chyme]      
Senneer[Blood]       
Oon[Muscle]      
Kozhuppu[Fat]      
Enbu[Bones]      
Moolai 
[Bonemarrow] 
     
Sukkilam/Suronitha
m[Genital 
discharges] 
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14. GENERAL EXAMINATION: 
 
General Examination: 
 
0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Height (cms)      
Weight (kg)      
Temperature(°F)         
Pulse rate (pe rmin)      
Heart rate (per min)      
Respiratoryrate(permin)      
Blood pressure(mm/Hg)      
Pallor      
Jaundice      
Cyanosis      
Lymphadenopathy      
Pedal edema      
Clubbing      
Jugular venous pulsation      
 
15. SYSTEMIC EXAMINATION: 
Systemic examination 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Locomotor system      
Cardio Vascular System  
 
    
Respiratory system       
 
    
Gastro Intestinal system     
 
    
Central Nervous System         
 
    
Urogenital system      
Endocrine System      
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16.Examinatiin Of Male Genitalia 
 
 Testis Epididymis Vas 
deferens  
Varicocele Hydrocele Hernia 
Right       
Left       
 
Examination of penis 
Prepuce External urethral meatus Glans penis Body of penis 
    
 
17. CLINICAL SYMPTOMS 
 
 
 
 
 
 
 
Date : 
 
Station: 
 
 
Signature of the Investigator: 
 
  
 
Signature of the Lecturer:     
 
 
     Signature of the HOD 
S.no CLINICAL 
SYMPTOMS 
0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
1 Premature 
ejaculation 
     
2 Nocturnal emission      
3 Erectile dysfunction      
4 Painful coitus      
5 Painful micuturition      
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  NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AAN MALADU ” (MALE INFERTILITY) AND THE 
DRUG OF CHOICE IS “POONAIKALI VITHAI CHOORANAM ”   
       FORM III 
LABORATORY INVESTIGATION ON ENROLLMENT
  
1. STUDY  NO______    2 OP NO_____________:  REG NO:  
 
3.  NAME_____________________   4.DATE OF  ASSESSMENT   :------------   
 
BLOOD INVESTIGATION NORMAL VALUES 
BEFORE  
TMT 
 
AFTER  
  TMT 
HB( gms%) 
M:13-18 
W:11-16 
  
 
T.RBC(million cells /cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
 
ESR (mm) 
½ hr. 
M:0-10 
W:0-20 
  
1 hr.   
T.WBC (cells /cu.mm)       4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Esonophils 1-6   
Basophils 0-1   
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Blood Investigation Normal Values 
Before 
TMT 
 Date: 
After 
 TMT 
Date 
Blood 
glucose 
(mg/dl) 
Fasting 70-100   
PP 80-140   
Random 100-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-250   
HDL 30-60   
LDL Upto 130   
VLDL 40   
TGL Upto 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
Serum Uric acid 
M:3-9 
W: 2.5-7.5 
  
LFT 
(mg/dl) 
Total bilirubin 0.3-1   
Direct bilirubin 0.1-0.3   
Indirect bilirubin 0.2-0.8   
Serum total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
Serum calcium 9-11   
Serum phosphorous 2-5   
SGOT (IU/L) 6-18   
SGPT (IU/l) 3-26   
Alkaline phosphatase 
mg/dl 
3-12   
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Special investigation: 
 
          Semen analysis: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before TMT(with Date) 
 
After TMT (With Date) 
 
Volume   
Colour   
Apperance   
Viscosity   
Liquefaction time   
Fructose   
Sperm count   
Motility   
Morphology   
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Date : 
Station: 
Signature of the Investigator:                                                            Signature 
of the HOD 
 
Signature of the Lecturer:     
 
     
 
 
 
 
 
 
 
 
 
URINE 
INVESTIGATION 
Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
NEIKURI   
MOTION TEST   
Ova   
Cyst   
Occult blood   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
       PRE CLINICAL AND CLINICAL STUDY ON “AAN MALADU ” (MALE INFERTILITY) AND            
                          THE DRUG OF CHOICE IS “POONAIKALI VITHAI CHOORANAM”                                
                                    FORM - IV  (DRUG COMPLIANCE FORM) 
 
NAME:  
DRUG NAME:  
On 1
st
day-Date:     Drugs issued:      Drugs returned:     
On 12
th
 day-Date:     Drugs issued:      Drugs returned:     
On 36
th
 day-Date:                                         Drugs issued:      Drugs returned:     
On 48
th
 day-Date:                                       Drugs issued:      Drugs returned 
Day    Date    Morning   Evening   Day     Date    Morning   Evening 
Day 1    Day25    
Day2    Day26    
Day3    Day27    
Day4    Day28    
Day5    Day29    
Day6    Day30    
Day7    Day31    
Day8    Day32    
Day9    Day33    
Day10    Day34    
Day11    Day35    
Day12    Day36    
Day13    Day37    
Day14    Day38    
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Date:          
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:   
                                                     Signature of the HOD 
 
    
 
 
 
 
 
Day15    Day39    
Day16    Day40    
Day17    Day41    
Day18    Day42    
Day19    Day43    
Day20    Day44    
Day21    Day45    
Day22    Day46    
Day23    Day47    
Day24    Day48    
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¬ñ ÁÄÎ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (“â¨É¸¡Ä¢ Å¢¨¾ ÝÃ½õ”¢) ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ  ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 FORM - V   ¾¸Åø ÀÊÅõ 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ ÁÕ.¸¢.þÃ¡§ƒó¾¢Ãý 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷   : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
         ¾¡õÀÃõ º¡É§¼¡Ã¢Âõ 
     ¦ºý¨É- 47 
ÁÕ.¸¢.þÃ¡§ƒó¾¢Ãý ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ 
ÀÂ¢ýÚ ÅÕ¸¢§Èý. ¬ñ ÁÄÎ ±ýÀÐ ÌÆó¨¾§ÀÚ ¯ÕÅ¡ì¸ ÓÊÂ¡¾ 
¿¢¨ÄÂ¡Ìõ, Å¢¨ÈôÒò ¾ý¨Á Ì¨È×, ¸ÉÅ¢ü Å¢óÐ ¸Æ¢¾ø, ÅÄ¢Ô¼ý ÜÊÂ 
¯È×, Å¢óÐ ÓóÐ¾ø, ¬¸¢Â ÌÈ¢Ì½í¸û ¸¡Ïõ. þó§¿¡öìÌ §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ 
ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç 
ÀÂýÀÎòÐõ §¿¡ì¸¢ø â¨É¸¡Ä¢ Å¢¨¾ ÝÃ½õ þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã 
¦ºö¸¢§Èý. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ 
ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. 
±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ 
¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 48¿¡ð¸û ¬Ìõ. 48 ¿¡ð¸ÙìÌ 
¦¾¡¼÷óÐ Àò¾¢Âõ ¸¡ì¸ §ÅñÎõ, þõÓ¨ÈôÀÊ  ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 12 
¿¡ð¸ÙìÌ ´Õ Ó¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. 48¿¡ð¸û ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ 
ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý 
¸ñ¼È¢ÂôÀÎõ. 
 
þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. 
¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ 
¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ. þó¾ ¬öÅ¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É 
¯Ú¾¢ «Ç¢ì¸¢§Èý.±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ 
¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ 
Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ 
ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û 
¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ. ¬ñ ÁÄÎ 
§¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø 
þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ, þó¾ ¬öÅ¢ø, ÁÕóÐ ¯ð¦¸¡ûÙõ 
¸¡Äò¾¢ø  Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø 
«¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ ¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ 
þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ 
ÓØ Í¾óò¾¢Ãõ ¾í¸ÙìÌ ¯ñÎ. §ÁÖõ ÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ 
þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ 
«È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
 
þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø 
ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. À¢È §º¡¾¨É ÀÊÅí¸Ç¢Öõ 
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¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î 
ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. 
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ¾¸Åø ÀÊ §¾÷× 
¦ºöÂôÀÎÅ£÷¸û.    
    
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û 
¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ 
ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å÷ 
ÁÕ.¸¢.þÃ¡§ƒó¾¢Ãý ¬¸¢Â ±ý¨É 8807565295 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò 
¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á 
ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ 
¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
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     NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
Preclinical and Clinical Study on  AAN MALDU (MALE INFERTILITY)and 
the drug of choice is “Poonaikali vithai chooranam”                                                                                                           
FORM V  – INFORMATION SHEET 
Name of the Principal Investigator : Dr.K.Rajendran 
Name of the Institution         : National Institute of Siddha,           
                                                        Tambaram Sanatorium, Chennai-47.   
      
   
Dr.K.Rajendran Studying M.D(S) in National Institute of Siddha, Chennai. The 
disease called AAN MALDU( male infertile)  symptoms like premature ejaculation, 
erectile dysfunction, nocturnal emission, painful coitus, painful micturition This 
condition is being treated in NIS with many siddha formulations. As a part of M.D(S) 
research programme and developing new efficacious medicines, I propose to study the 
Poonaikali vithai chooranam formulation for treating the condition. This 
formulation has been mentioned in siddha literature and empirical evidence with 
contemporary tools are required for documentation. You can receive medicines at free 
of cost.“Poonaikali vithai chooranam”can be taken twice daily with milk 48 days. 
The diagnosis tests will be carried out at free of cost. I  will assess the effect of 
treatment after completion of 48 days of treatment using clinical and lab parameters. 
 
 In this regard, Ineed to ask you few questions. I will maintain confidentiality of 
your comments and data obtained from you. There will be no risk of disclosing 
your identity and no physical, psychological or professional risk is involved by 
taking part in this study. 
 
 Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. You can choose not to answer any specific question. 
There is no specific benefit for you if you take part in the study, but you will be 
under our clinical monitoring and specific attention will be given for your health. 
Taking part in the study may be of benefit to the community, as it may help us to 
develop medicine for aan maldu.  In case of any adverse symptoms which is 
expected for few .patients during the treatment, shall be reported to Principle 
investigator  and care will be taken in NIS for relief. You can withdraw from the 
study at the midst of treatment period, if you are not interested to continue and 
you will receive our regular out patient treatment without any condition. 
 
 The information we will collect in this study, will be kept confidential  remain 
between you and the principal investigator. We will ask you a few questions 
through questionnaire. I will not write your name on other investigation  forms 
which we will  sent for different investigating/analysis sections and we will use a 
code instead given by the principal investigator. Only the principal investigator 
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will know the key to this code which will be kept in safe custody. If you agree to 
be a participant in this study, you will be screened as per the study protocol.  
 
 If you wish to find out more about this study before taking part, you can ask me 
all the questions you want or contact Dr.K.Rajendran PG scholar (Mobile phone 
no:8807565295 cum principal investigator of this study, attached to the National 
Institute of Siddha, Chennai. You can also contact the Chairman/Member-
secretary of Ethics committee, National Institute of Siddha, Chennai – 600047, 
Tel no: 91-44-22411611, for rights and participation in the study. 
 
 
 
 
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “AAN MALADU ” (MALE INFERTILITY) AND THE 
  DRUG OF CHOICE IS “POONAIKALI VITHAI  CHOORANAM                                                         
        FORM VII  ADVERSE DRUG  REACTION FORM / PHARMACOVIGILENCE FORM 
 
1. STUDY  NO______    2 OP NO_____________:                            REG NO: 321411207/2014-17 
 
3.  NAME_____________________   4.DATE OF  ASSESSMENT   :-------------------- 
NATIONAL PHARMACOVIGILANCE PROGRAMME 
FOR  SIDDHA DRUGS 
 
 
 
 
Please note:  i.  All consumers / patients and reporters information will remain 
confidential. 
ii. It is requested to report all suspected reactions to the concerned, even if  
             it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
 
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / 
Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes 
below) 
 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
 
 
 
 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used 
by the patient during the reporting period: 
 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha 
 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
 
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision 
or used as self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result  of the adverse reaction / side effect / untoward effects (please 
complete the boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes 
specify:  
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8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
Signature of the reporter:       Date: 
 
Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha 
Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 
22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation 
/occurrence of ADR   
 
 
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
         Signature of the HOD 
 
 
 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
Name & address of the RRC-
ASU / PPC-ASU 
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CTRI No  CTRI 2016/07/011882  
Acknowledge
ment Number  
REF/2016/07/011882  
Last Modified 
On: 
22/03/2017 
Post Graduate 
Thesis  
Yes  
Type of Trial  Interventional  
Type of Study   
Drug 
Medical Device 
Siddha 
Diagnostic 
Screening 
Other (Specify)  
Study Design  Other  
Public Title of 
Study  
Clarification(s) 
with Reply  
Modification(s)   
Poonaikalivithai chooranam in treatment of Aan maladu(Male 
infertility)  
Scientific Title 
of Study  
Clarification(s) 
with Reply  
Modification(s)   
Clinical study on Aan Maladu(Male infertility) and the drug of 
choice is Poonaikalivithai chooranam(internal)  
Acronym  POONAIKALIVITHAI CHOORANAM  
Secondary IDs 
if Any   
Secondary ID  Identifier  
NIL  NIL  
  
Details of 
Principal 
Investigator 
or overall Trial 
Coordinator 
(multi-center 
study)  
Clarification(s) 
with Reply  
Modification(s)   
Name  Dr K RAJENDRAN  
Designation  PG SCHOLAR  
Affliation  NATIONAL INSTITUTE OF SIDDHA  
Address  
NATIONAL INSTITUTE OF SIDDHA DEPT OF 
MARUTHUVAM TAMBARAM SANATORIUM 
KANCHEEPURAM 600047 
NATIONAL INSTITUTE OF SIDDHA DEPT OF 
MARUTHUVAM TAMBARAM SANATORIUM 
KANCHEEPURAM 600047 
Kancheepuram 
TAMIL NADU 
600047 
India  
Phone  8807565295   
Fax     
Email  drrajendrankrish@gmail.com   
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Details 
Contact 
Person 
Scientific 
Query  
Clarification(s) 
with Reply  
Modification(s)   
Name  DR PERIYASAMY PANDIAN  
Designation  ASSOSIATE PROFESSOR  
Affliation  NATIONAL INSTITUTE OF SIDDHA  
Address  
DEPT OF MARUTHUVAM NATIONAL INSTITUTE 
SIDDHA TAMBARAM SANATORIUM 
KANCHEEPURAM 600047 
DEPT OF MARUTHUVAM NATIONAL INSTITUTE 
SIDDHA TAMBARAM SANATORIUM 
KANCHEEPURAM 600047 
Kancheepuram 
TAMIL NADU 
600047 
India  
Phone  9884878469   
Fax  044-22381314   
Email  periasamypandian22@gmail.com   
  
Details 
Contact 
Person 
Public Query  
Clarification(s) 
with Reply  
Modification(s)   
Name  DR LAKSHMIKANTHAM  
Designation  LECTURER  
Affliation  NATIONAL INSTITUTE OF SIDDHA  
Address  
DEPT OF MARUTHUVAM NATIONAL INSTITUTE 
SIDDHA TAMBARAM SANATORIUM 
KANCHEEPURAM 600047 
DEPT OF MARUTHUVAM NATIONAL INSTITUTE 
SIDDHA TAMBARAM SANATORIUM 
KANCHEEPURAM 600047 
Kancheepuram 
TAMIL NADU 
600047 
India  
Phone  9444466880   
Fax  044-22381314   
Email  drlakshmiramaswamy@gmail.com   
  
Source of 
Monetary or 
Material 
Support  
Clarification(s) 
with Reply   
AYOTHIDOSS PANDITHAR HOSPITAL  
  
Primary 
Sponsor  
Clarification(s) 
with Reply   
Name  AYOTHIDOSS PANDITHAR HOSPITAL  
Address  
NATIONAL INSTITUTE SIDDHA TAMBARAM 
SANATORIUM KANCHEEPURAM   
Type of 
Sponsor  
Research institution and hospital  
  
Details of Name  Address  
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Secondary 
Sponsor   
NIL  NIL  
  
Countries of 
Recruitment   
  India   
Sites of Study  
Clarification(s) 
with Reply   
No of Sites = 1   
Name of 
Principal 
Investigat
or  
Name of 
Site  
Site 
Address  
Phone/Fax/Email  
DR K 
RAJENDRA
N  
DR K 
RAJENDR
AN  
DEPT OF 
MARUTHUVA
M NATIONAL 
INSTITUTE 
SIDDHA 
TAMBARAM 
SANATORIU
M 
KANCHEEPUR
AM 600047 
Kancheepura
m 
TAMIL NADU  
8807565295 
 
drrajendrankrish@gmail
.com  
  
Details of 
Ethics 
Committee  
Clarification(s) 
with Reply   
No of Ethics Committees= 1   
Name of 
Committee  
Approval 
Status  
Date of 
Approval  
Approval 
Document  
Is 
IEC?  
INSTITUTINAL 
ETHICAL 
COMMITTEE  
Approved  26/08/2015  
Approval 
File  
No  
  
Regulatory 
Clearance 
Status from 
DCGI   
Status  Date  Aproval Document  
Not Applicable  No Date Specified  No File Uploaded  
  
Health 
Condition / 
Problems 
Studied  
Clarification(s) 
with Reply   
Health Type  Condition  
Patients  AAN MALADU(Male Infertility)  
  
Intervention / 
Comparator 
Agent 
Clarification(s) 
with Reply   
Type  Name  Details  
Comparator 
Agent  
NIL  NIL  
Intervention  
POONAIKALIVITHAI 
CHOORANAM(MALE 
INFERTILITY)  
6g of poonaikalivithai 
chooranam twice a 
day orally a period of 
48days  
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Inclusion 
Criteria   
Age 
From  
21.00 Year(s) 
Age To  45.00 Year(s) 
Gender  Male  
Details  
1.Male infertile 
2.Age 21-45 year 
3.Maritial status-more than 1 year 
4.Sperm count ≤ 40 million/ejaculation 
5.Motility less than ≤ 50% 
6.Patient who willing to sign the informed consent 
stating that he will continuously stick to the 
treatment during 48days but can opt out of the trial 
of his own conscious discretion 
Patients who are willing to give specimen of blood 
,urine and semen before and after treatment.  
  
Exclusion 
Criteria  
Details  
1.Azoospermia 
2.Hydrocele 
3.Diabetes mellitus 
4.Hypertension 
5.Endocrine disorder 
6.Cardiac disease 
7.VDRL & STD 
8.Inguinal Hernia 
9.Renal disease 
10.Varicose veins  
  
Method of 
Generating 
Random 
Sequence  
Not Applicable  
Method of 
Concealment   
Case Record Numbers  
Blinding/Mask
ing  
Open Label  
Primary 
Outcome  
Clarification(s) 
with Reply   
Outcome  TimePoints  
Primary Outcome is mainly 
assessed by increase in the 
sperm count and motility % 
  
Primary Outcome is mainly 
assessed by increase in the 
sperm count and motility % 
  
  
Secondary 
Outcome  
Clarification(s) 
with Reply   
Outcome  TimePoints  
Secondary Out Come is 
mainly assessed by reduce 
the clinical symptoms.  
Secondary Out Come is mainly 
assessed by reduce the clinical 
symptoms.  
  
Target Sample 
Size   
Total Sample Size="40" 
Sample Size from India="40"  
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Phase of Trial   Phase 3  
Date of First 
Enrollment 
(India)  
Clarification(s) 
with Reply  
Modification(s)   
16/05/2016  
Date of First 
Enrollment 
(Global)  
No Date Specified  
Estimated 
Duration of 
Trial   
Years="0" 
Months="6" 
Days="0"  
Recruitment 
Status of Trial 
(Global)  
Clarification(s) 
with Reply  
Modification(s)   
Not Applicable  
Recruitment 
Status of Trial 
(India)  
Open to Recruitment  
Publication 
Details   
NONE YET  
Brief 
Summary   
It is single non-ranomized, open-label trial to determine the 
efficacy of POONAIKALIVITHAI CHIIRANAM(prepared from 
herbal ) in patients with Aan Maladu(MALE INFERTILITY).In this 
trial 40 patients will be recruited and the trial drug will be 
administered 6g twice a day for a period of 48days. During the 
trial period if any AE/SAE/SUSAR will be noticed and refered to 
pharmacovigilance dept in NIS and further management will 
 also be given in NIS OPD/IPD.The entire trial will be monitored 
by the research monitoring committee of NIS. During this trial 
all the safety efficacy parameters will be recorded in the CRF. 
After completion of  the trial all the study related data will be 
analysed statistically.The outcome of this trial will be published 
in Indian journal of Medical Research.  
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